Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:23:44 ON 05 JAN 2010

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	0.44

FILE 'REGISTRY' ENTERED AT 11:24:48 ON 05 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JAN 2010 HIGHEST RN 1200403-72-0
DICTIONARY FILE UPDATES: 4 JAN 2010 HIGHEST RN 1200403-72-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10821545 updated.str





chain nodes :
10 11 12 19
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17
chain bonds :
1-10 10-11 11-12 11-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-14 8-9 8-17 14-15 15-16 16-17

exact/norm bonds :
1-10 6-9 8-9 10-11 11-12 11-19
exact bonds :
5-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-14 8-17 14-15 15-16 16-17
isolated ring systems :
containing 1 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s L1 SSS full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 11:25:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2080 TO ITERATE

100.0% PROCESSED 2080 ITERATIONS 445 ANSWERS
SEARCH TIME: 00.00.01

L2 445 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	191.54	191.98

FILE 'CAPLUS' ENTERED AT 11:25:29 ON 05 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Jan 2010 VOL 152 ISS 2
FILE LAST UPDATED: 4 Jan 2010 (20100104/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L2 SSS full
L3 44 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 44 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:901979 CAPLUS Full-text
DOCUMENT NUMBER: 151:417661
TITLE: Targeting transcription factor NFκB: Comparative analysis of proteasome and IKK inhibitors
AUTHOR(S): Gasparian, Alexander V.; Guryanova, Olga A.; Chebotaev, Dmitry V.; Shishkin, Alexander A.; Yemelyanov, Alexander Y.; Budunova, Irina V.

CORPORATE SOURCE: Cleveland Biolabs, Inc., Buffalo, NY, USA
SOURCE: Cell Cycle (2009), 8(10), 1559-1566
CODEN: CCEYAS; ISSN: 1538-4101
PUBLISHER: Landes Bioscience
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Nuclear factorκB (NFκB) plays a critical role in cancer development and progression. Thus, the NFκB signaling pathway provides important targets for cancer chemoprevention and anticancer chemotherapy. The central steps in NFκB activation are phosphorylation and proteasome-dependent degradation of its inhibitory proteins termed IκBs. Consequently, the major pharmacol. approaches to target NFκB include repression of IκB kinases (IKKs) and blocking the degradation of IκBs by proteasome inhibitors. The authors quant. compared the efficacy of various proteasome inhibitors (MG132, lactacystin and epoxomicin) and IKK inhibitors (BAY 11-7082 and PS1145) to block NFκB activity induced by TNFα or TPA and to sensitize LNCaP prostate carcinoma cells to apoptosis. The authors' studies revealed significant differences between these two classes of NFκB inhibitors. The authors found that proteasome inhibitors epoxomicin and MG132 attenuated NFκB induction much more effectively than the IKK inhibitors. Furthermore, in contrast to IKK inhibitors, all studied proteasome inhibitors specifically blocked TPA-induced generation de novo of NFκB p50 homodimers-(p50/p50). These results suggest that the proteasome plays a dominant role in TPA-induced formation of functional p50 homodimers, while IKK activity is less important for this process. Interestingly, profound attenuation of p50/p50 DNA-binding does not reduce the high potency of proteasome inhibitors to suppress NFκB-dependent transcription. Finally, proteasome inhibitors were much more effective in sensitizing LNCaP cells to TNFα-induced apoptosis compared to IKK inhibitors at the concns. when both types of agents similarly attenuated NFκB activity. The authors conclude that this remarkable pro-apoptotic potential of proteasome inhibitors is partially mediated through NFκB-independent mechanism.

IT 431898-65-6, PS1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of proteasome and IKK inhibitors on transcription factor NFκB activity and relation to LNCaP sensitization)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:649786 CAPLUS Full-text
DOCUMENT NUMBER: 150:564026
TITLE: Preparation of beta carbolines as IKK-2 inhibitors
INVENTOR(S): Elder, Amy M.; Ghosh, Shomir; Harrison, Sean J.; Hepperle, Michael E.; Liu, Julie Fields; Murray, Robert S.; Renou, Christelle C.; Reynolds, Dominic
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 125pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009067233	A1	20090528	WO 2008-US12966	20081120
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-3777P P 20071120
OTHER SOURCE(S): MARPAT 150:564026
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention provides beta-carboline compds. of formula [I; R1 = H, halo, C1-3 aliphatic, amino, cyano, mono- or di(C1-3 alkyl)amino, C1-3 alkoxy, CONH2, NHCOCF3, CH2NH2; R2 = H, halo, C1-4 aliphatic, C1-2 alkoxy, C1-2 haloalkyl; R3 = H, halo, C1-6 aliphatic, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, HO, NH2, cyano, mono- or di(C1-6alkyl)amino; R4 = (un)substituted C1-6 aliphatic, etc.; x = 0-4; G = (un)substituted C1-3 alkyl; R5 = Q, Q1, Q2, Q3, Q4; X = (un)substituted NH, O, S; n = 1-3; m = 0-6; R6 = oxo, R8, T-R8, or V-T-R8, etc.; R8 = halo, OR8a, cyano, SR8a, S(O)2R8a, S(O)R8a, C(O)R8a, CO2R8a, N(R8a)2, C(O)N(R8a)2, N(R8a)C(O)R8a, N(R8a)CO2R8a, etc.; T = (un)substituted straight or branched C1-6 alkylene; V = O, S, S(O), S(O)2, C(O), CO2, each (un)substituted NH, C(O)NH, NHC(O), NHCO2, or S(O)2NH, etc.; R8a = H, each (un)substituted C1-6 aliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl; R7 = H, R9, Q-R10, or W-Q-R10, etc.; R9 = S(O)2R9b, S(O)R9b, C(O)R9b, CO2R9b, C(O)N(R9a)2, S(O)2N(R9a)2, etc.; Q = (un)substituted straight or branched C1-6alkylene chain; W = S(O), S(O)2, C(O), CO2, each (un)substituted C(O)NH or S(O)2NH; R9a = H, R9b; R9b = each (un)substituted C1-6 aliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl] or pharmaceutically acceptable salts thereof were prepared The compds. are useful for treating cancer and inflammatory disorders, and immune-related diseases. Thus, 0.369 g (3S)-5-(6-chloro-9H-pyrido[3,4-b]indol-8-

ylcarbamoyl)-2,2- dimethylmorpholine-4-carboxylic acid tert-Bu ester was dissolved in 2.00 mL MeOH, cooled to 0°, treated with 4.0 M HCl/dioxane (2.00 mL), and stirred for 15 min before removing the ice bath and then at room temperature for 1 h to give (3S)-5-(6-chloro-9H-pyrido[3,4-b]indol-8-ylcarbamoyl)-2,2- dimethylmorpholine hydrochloride (II) as a yellow powder. II was dissolved in 4.0 mL MeOH, treated with 98 mg 1-ethyl-1H-imidazole-2-carboxaldehyde and then with 50 mg sodium cyanoborohydride, and the resulting suspension was stirred at room temperature for 3 h to give (3S)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl- 1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide triformate which was converted into (3S)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4- [(1-ethyl-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride (III). The IKB kinase inhibition average IC50 values for the inventive compds. I were generally below .apprx.10 μM.

IT 783349-90-6P, (S)-5-[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)carbamoyl]-2,2-dimethylmorpholine 1157075-92-7P, (3S)-5-[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)carbamoyl]-2,2-dimethylmorpholine hydrochloride 1157076-02-2P, (3S)-5-[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)carbamoyl]-2,2-dimethylmorpholine trifluoroacetate 1157076-09-9P, (3S)-3-[[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]morpholine trifluoroacetate
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of beta carbolines as IKK-2 inhibitors for treating cancer and inflammatory disorders, and immune-related diseases)

RN 783349-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157075-92-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:?), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



x HCl

RN 1157076-02-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 783349-90-6
CMF C18 H19 Cl N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-09-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1157076-08-8

CMF C16 H15 Cl N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 783349-81-5P, (3S)-4-((2S)-2-Aminopropyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-72-6P 1157077-26-3P, (3S)-4-(2-Aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of beta carbolines as IKK-2 inhibitors for treating cancer and inflammatory disorders, and immune-related diseases)

RN 783349-81-5 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 783349-80-4
CMF C21 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-72-6 CAPLUS
CN Carbamic acid, N-[(1S)-2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-26-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157077-25-2

CMF C20 H24 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 1157075-93-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide
1157075-94-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide triformate 1157075-97-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-03-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(4-methyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]morpholine-3-carboxamide
1157076-12-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(6,8-diazaspiro[3.5]non-6-en-7-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-18-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)methyl]morpholine-3-carboxamide
1157076-19-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)methyl]morpholine-3-carboxamide formate 1157076-34-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(dimethylamino)-2-iminoethyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-40-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2-hydroxyethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide
1157076-43-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-50-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide
1157076-82-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,3-oxazol-5-yl)methyl]morpholine-3-carboxamide

1157076-85-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,4,5,6-tetrahydropyrimidin-2-yl)methyl]morpholine-3-carboxamide 1157077-31-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4-isopropyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-35-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(4-phenyl-5,6-dihydro-4H-1,3-oxazin-2-yl)methyl]morpholine-3-carboxamide 1157077-49-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-[2-(dimethylamino)-2-oxoethyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-50-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-51-4P, Methyl 2-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethylmorpholin-4-yl]methyl]-4,5-dihydro-1H-imidazole-5-carboxylate 1157077-52-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-3-yl)methyl]morpholine-3-carboxamide 1157077-53-6P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl]morpholine-3-carboxamide 1157077-54-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-isopropyl-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-55-8P, (3S)-4-[[1-(2-Amino-2-oxoethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide 1157077-56-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide 1157077-57-0P, (3S)-4-[(1-Benzyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide 1157077-58-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(cyclohexylmethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-59-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-difluoro-1,4,5,6-tetrahydropyrimidin-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-60-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-61-6P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-dimethyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl]morpholine-3-carboxamide 1157077-62-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,4,5,6-tetrahydropyrimidin-2-yl)methyl]morpholine-3-carboxamide 1157077-63-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-64-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-(1H-imidazol-1-yl)propyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-65-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-dimethyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-66-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-67-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((7aS)-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazol-3-yl)methyl]morpholine-3-carboxamide 1157077-68-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2-hydroxy-2-methylpropyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-69-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl]morpholine-3-carboxamide

1157077-70-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,3-thiazol-2-yl)methyl]morpholine-3-carboxamide 1157077-71-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,4-dimethyl-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-72-9P, Ethyl 2-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethylmorpholin-4-yl]methyl]-4,5-dihydro-1H-imidazole-5-carboxylate 1157077-73-0P, (3S)-4-(2-Amino-2-iminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)morpholine-3-carboxamide 1157077-74-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3,5-dichloropyridin-4-yl)methyl]morpholine-3-carboxamide 1157077-75-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-76-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-77-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide 1157077-78-5P, (3S)-4-[(1-Butyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide 1157077-79-6P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]morpholine-3-carboxamide 1157077-80-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-1H-imidazol-2-yl)methyl]morpholine-3-carboxamide 1157077-81-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)methyl]morpholine-3-carboxamide 1157077-82-1P, Ethyl 2-[2-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethylmorpholin-4-yl]methyl]-4,5-dihydro-1H-imidazol-1-yl]acetate 1157077-83-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-isopropyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-84-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1H-imidazol-1-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-85-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(imidazo[1,5-a]pyridin-3-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-86-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-cyclopentyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-87-6P 1157077-88-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-dimethylpropyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-89-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-90-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of beta carbolines as IKK-2 inhibitors for treating cancer and inflammatory disorders, and immune-related diseases)

RN 1157075-93-8 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157075-94-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1157075-93-8
CMF C24 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 1157075-97-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157075-96-1
CMF C24 H29 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-03-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-4-methyl-2-oxazolyl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-12-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157076-18-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)methyl]-, (3S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-19-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1157076-18-0
CMF C26 H29 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 1157076-34-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157076-40-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157076-43-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-50-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157076-82-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(5-oxazolylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-85-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-31-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-35-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-49-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-[2-(dimethylamino)-2-oxoethyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-50-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,5-dihydro-4,4-dimethyl-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-51-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-52-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-53-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-5-methyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-54-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-55-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-56-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-57-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-58-1 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(cyclohexylmethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-59-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-difluoro-1,4,5,6-tetrahydro-2-pyrimidinyl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-60-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-5,5-dimethyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-61-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,4,5,6-tetrahydro-5,5-dimethyl-2-pyrimidinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-62-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-63-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-64-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-(1H-imidazol-1-yl)propyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-65-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-66-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(1H-imidazol-2-ylmethyl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-67-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-68-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-69-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-1-methyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-70-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(2-thiazolylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-71-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-72-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-73-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-amino-2-iminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-74-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3,5-dichloro-4-pyridinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-75-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-76-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-77-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-78-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-79-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-80-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-1H-imidazol-2-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-81-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-82-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-83-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-84-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-85-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(imidazo[1,5-a]pyridin-3-ylmethyl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-86-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-cyclopentyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-87-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-88-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-dimethylpropyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-89-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1157077-90-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 1157075-91-6P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157075-95-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-00-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]morpholine-3-carboxamide 1157076-01-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((4S)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]morpholine-3-carboxamide 1157076-07-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1H-pyrazol-3-yl)methyl]morpholine-3-carboxamide 1157076-10-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((4S)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]morpholine-3-carboxamide 1157076-11-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-[2-(dimethylamino)-2-oxoethyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-13-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(6,8-diazaspiro[3.5]non-6-en-7-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-15-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-dimethyl-5,6-dihydro-4H-1,3-oxazin-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-17-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157076-20-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,3-thiazol-2-yl)methyl]morpholine-3-carboxamide 1157076-21-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-23-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3-fluoropyridin-4-yl)methyl]morpholine-3-carboxamide 1157076-24-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-1,3-oxazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-25-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-26-0P, (3S)-2-[[5-[[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethylmorpholin-4-yl]methyl]-4,5-dihydro-1H-imidazole-5-carboxylic acid methyl ester trihydrochloride 1157076-28-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4-methyl-1H-imidazol-5-yl)methyl]morpholine-3-carboxamide

1157076-29-3P, (3S)-4-[(Benzo[b]thien-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide dihydrochloride 1157076-30-6P, (3S)-4-[(Benzo[b]thien-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide 1157076-31-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-3-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157076-35-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(dimethylamino)-2-iminoethyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-37-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(4-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl]morpholine-3-carboxamide tris(trifluoroacetate) 1157076-38-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(pyridin-4-yl)methyl]morpholine-3-carboxamide 1157076-39-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-isopropyl-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-41-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2-hydroxyethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-44-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-46-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(6-methylpyridin-2-yl)methyl]morpholine-3-carboxamide 1157076-47-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(3-oxa-1-azaspiro[4.4]non-1-en-2-yl)methyl]morpholine-3-carboxamide 1157076-49-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide trihydrochloride 1157076-51-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(pyrimidin-2-yl)methyl]morpholine-3-carboxamide 1157076-52-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[((4R)-4-isobutyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-54-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(pyridin-3-yl)methyl]morpholine-3-carboxamide 1157076-55-5P, (3S)-4-[[1-(2-Amino-2-oxoethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-57-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide trihydrochloride 1157076-58-8P, (3S)-4-[(1-Benzyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-59-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(cyclohexylmethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-61-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-difluoro-1,4,5,6-tetrahydropyrimidin-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-64-6P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-66-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-dimethyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157076-68-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,4,5,6-tetrahydropyrimidin-2-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157076-69-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3a,4,5,6,7,7a-hexahydro-

1H-benzimidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-71-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-(1H-imidazol-1-yl)propyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-73-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-dimethyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-75-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,7-diazaspiro[2.5]oct-5-en-6-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide tris(trifluoroacetate) 1157076-77-1P, (3S)-4-[(1H-Indol-3-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)morpholine-3-carboxamide 1157076-78-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-80-6P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((7aS)-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazol-3-yl)methyl]morpholine-3-carboxamide tris(trifluoroacetate) 1157076-83-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,3-oxazol-5-yl)methyl]morpholine-3-carboxamide tris(trifluoroacetate) 1157076-84-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157076-86-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,4,5,6-tetrahydropyrimidin-2-yl)methyl]morpholine-3-carboxamide tris(trifluoroacetate) 1157076-87-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(pyrazin-2-yl)methyl]morpholine-3-carboxamide 1157076-88-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2-hydroxy-2-methylpropyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-90-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-4,5-dihydro-1H-imidazol-2-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157076-91-9P, (3S)-4-[(1,3-Benzothiazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide 1157076-92-0P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,3-thiazol-2-yl)methyl]morpholine-3-carboxamide dihydrochloride 1157076-93-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]morpholine-3-carboxamide 1157076-94-2P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,4-dimethyl-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157076-96-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,3-oxazol-2-yl)methyl]morpholine-3-carboxamide 1157076-97-5P, (3S)-2-[[5-[[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethylmorpholin-4-yl]methyl]-4,5-dihydro-1H-imidazole-5-carboxylic acid ethyl ester trihydrochloride 1157076-99-7P, (3S)-4-(2-Amino-2-iminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)morpholine-3-carboxamide trihydrochloride 1157077-00-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2,5-dichloropyridin-4-yl)methyl]morpholine-3-carboxamide 1157077-01-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-methyl-1H-indol-3-yl)methyl]morpholine-3-carboxamide 1157077-02-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-04-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-06-9P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2-phenyl-1H-imidazol-5-

yl)methyl]morpholine-3-carboxamide 1157077-07-0P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1H-pyrazol-3-yl)methyl]morpholine-3-carboxamide 1157077-08-1P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide trihydrochloride 1157077-10-5P,
(3S)-4-[(1-Butyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-11-6P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157077-12-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]morpholine-3-carboxamide trihydrochloride 1157077-13-8P 1157077-14-9P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(pyrimidin-5-yl)methyl]morpholine-3-carboxamide 1157077-15-0P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1H-imidazol-5-yl)methyl]morpholine-3-carboxamide 1157077-17-2P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(4,4,6-trimethyl-5,6-dihydro-4H-1,3-oxazin-2-yl)methyl]morpholine-3-carboxamide 1157077-18-3P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5-methoxy-1H-indol-3-yl)methyl]morpholine-3-carboxamide 1157077-19-4P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1H-imidazol-2-yl)methyl]morpholine-3-carboxamide 1157077-20-7P,
2-[2-[[(5S)-5-[[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethylmorpholin-4-yl]methyl]-4,5-dihydro-1H-imidazol-1-yl]acetic acid ethyl ester trihydrochloride 1157077-24-1P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1H-imidazol-1-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-28-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[((4S)-4-isopropyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-29-6P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[((4R)-4-isopropyl-4,5-dihydro-1,3-oxazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide 1157077-32-1P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((4S)-4-phenyl-5,6-dihydro-4H-1,3-oxazin-2-yl)methyl]morpholine-3-carboxamide 1157077-33-2P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[((4R)-4-phenyl-5,6-dihydro-4H-1,3-oxazin-2-yl)methyl]morpholine-3-carboxamide 1157077-36-5P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(imidazo[1,5-a]pyridin-3-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-37-6P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1H-imidazol-1-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-38-7P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-cyclopentyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-40-1P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-[(pyridin-3-yl)methyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]morpholine-3-carboxamide dihydrochloride 1157077-42-3P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-dimethylpropyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethylmorpholine-3-carboxamide dihydrochloride 1157077-45-6P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(pyrimidin-5-yl)methyl]morpholine-3-carboxamide 1157077-46-7P,
(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride 1157077-47-8P, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)ethyl]-6,6-dimethylmorpholine-3-carboxamide trihydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of beta carbolines as IKK-2 inhibitors for treating cancer and inflammatory disorders, and immune-related diseases)

RN 1157075-91-6 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157075-95-0 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-00-0 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4R)-4,5-dihydro-4-methyl-2-oxazolyl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-01-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4S)-4,5-dihydro-4-methyl-2-oxazolyl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-07-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(1H-pyrazol-3-ylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-10-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4S)-4,5-dihydro-4-phenyl-2-oxazolyl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-11-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-[2-(dimethylamino)-2-oxoethyl]-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



3 HCl

RN 1157076-13-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(6,8-diazaspiro[3.5]non-6-en-7-ylmethyl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-12-4
CMF C26 H31 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-15-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,6-dihydro-5,5-dimethyl-4H-1,3-oxazin-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-17-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-20-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(2-thiazolylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-21-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,5-dihydro-4,4-dimethyl-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-23-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3-fluoro-4-pyridinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-24-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-2-oxazolyl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-25-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-4,4-dimethyl-2-oxazolyl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-26-0 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]methyl]-4,5-dihydro-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-28-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4-methyl-1H-imidazol-5-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-29-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-(benzo[b]thien-2-ylmethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1157076-30-6 CAPLUS
CN 3-Morpholinecarboxamide, 4-(benzo[b]thien-2-ylmethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-31-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-3-yl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-35-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(dimethylamino)-2-iminoethyl]-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-34-0
CMF C22 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-37-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-5-methyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3R)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-36-2
CMF C23 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-38-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(4-pyridinylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-39-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-(1-methylethyl)-1H-imidazol-2-yl]methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-41-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-(2-hydroxyethyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-40-8
CMF C24 H29 Cl N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-44-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)methyl]-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-43-1
CMF C26 H31 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-46-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(6-methyl-2-pyridinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-47-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(3-oxa-1-azaspiro[4.4]non-1-en-2-ylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-49-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl]methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-51-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(4-pyrimidinylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-52-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4R)-4,5-dihydro-4-(2-methylpropyl)-2-oxazolyl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-54-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(3-pyridinylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-55-5 CAPLUS
CN 3-Morpholinecarboxamide, 4-[[1-(2-amino-2-oxoethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



3 HCl

RN 1157076-57-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-58-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-59-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(cyclohexylmethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-61-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(7-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,5-difluoro-1,4,5,6-tetrahydro-2-pyrimidinyl)methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-64-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(7-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-5,5-dimethyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-63-5
CMF C24 H29 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-66-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,4,5,6-tetrahydro-5,5-dimethyl-2-pyrimidinyl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-68-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-69-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(7-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-71-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-(1H-imidazol-1-yl)propyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-73-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,4,5,6-tetrahydro-5,5-dimethyl-2-pyrimidinyl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-75-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(5,7-diazaspiro[2.5]oct-5-en-6-ylmethyl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-74-8
CMF C25 H29 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-77-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(1H-indol-3-ylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-78-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(1H-imidazol-2-ylmethyl)-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-80-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(7aS)-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazol-3-yl]-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-79-3
CMF C24 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-83-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(5-oxazolylmethyl)-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-82-8
CMF C22 H22 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-84-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-86-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)methyl]-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 1157076-85-1
CMF C23 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1157076-87-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(2-pyrazinylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-88-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-(2-hydroxy-2-methylpropyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



3 HCl

RN 1157076-90-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(4,5-dihydro-1-methyl-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-91-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-benzothiazolylmethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-92-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(2-thiazolylmethyl)-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1157076-93-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-94-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-4,4-dimethyl-1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-96-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(2-oxazolylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-97-5 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]methyl]-4,5-dihydro-, ethyl ester, hydrochloride (1:3) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157076-99-7 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-amino-2-iminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-00-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2,5-dichloro-4-pyridinyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-01-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-methyl-1H-indol-3-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-02-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl)ethyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-04-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-difluoroethyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-06-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2-phenyl-1H-imidazol-5-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-07-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(1H-pyrazol-3-ylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-08-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-10-5 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(1-butyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-11-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-12-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-13-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)methyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-14-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(5-pyrimidinylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-15-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(1H-imidazol-5-ylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-17-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5,6-dihydro-4,4,6-trimethyl-4H-1,3-oxazin-2-yl)methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-18-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(5-methoxy-1H-indol-3-yl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-19-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(1H-imidazol-2-ylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-20-7 CAPLUS
CN 1H-Imidazole-1-acetic acid, 2-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]methyl]-4,5-dihydro-, ethyl ester, hydrochloride (1:3) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-24-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1H-imidazol-1-yl)ethyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl

RN 1157077-28-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4S)-4,5-dihydro-4-(1-methylethyl)-2-oxazolyl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-29-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4R)-4,5-dihydro-4-(1-methylethyl)-2-oxazolyl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-32-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4S)-5,6-dihydro-4-phenyl-4H-1,3-oxazin-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-33-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[(4R)-5,6-dihydro-4-phenyl-4H-1,3-oxazin-2-yl]methyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-36-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-(imidazo[1,5-a]pyridin-3-ylmethyl)-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-37-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-(1-methylethyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-38-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(1-cyclopentyl-4,5-dihydro-1H-imidazol-2-yl)methyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-40-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[4,5-dihydro-1-(3-pyridinylmethyl)-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1157077-42-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[[1-(2,2-dimethylpropyl)-4,5-dihydro-1H-imidazol-2-yl]methyl]-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1157077-45-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-(5-pyrimidinylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-46-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 1157077-47-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)ethyl]-6,6-dimethyl-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

IT 1157077-16-1P, (3S)-4-[(1H-Benzimidazol-2-yl)methyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of beta carbolines as IKK-2 inhibitors for treating cancer and inflammatory disorders, and immune-related diseases)

RN 1157077-16-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-(1H-benzimidazol-2-ylmethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783349-59-7, (3S)-3-[[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]morpholine-4-carboxylic acid tert-butyl ester 783349-79-1, (S)-5-[(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)carbamoyl]-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester 1157076-08-8, (3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)morpholine-3-carboxamide 1157077-27-4,

(3S)-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethylmorpholine-3-carboxamide bis(trifluoroacetate)
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of beta carbolines as IKK-2 inhibitors for treating cancer and inflammatory disorders, and immune-related diseases)

RN 783349-59-7 CAPLUS
CN 4-Morpholinecarboxylic acid, 3-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-79-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157076-08-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1157077-27-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 783349-90-6
CMF C18 H19 Cl N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:523496 CAPLUS Full-text
DOCUMENT NUMBER: 150:501210
TITLE: Mesylate salt of an IKK inhibitor
INVENTOR(S): Hicks, Frederick A.; Cooper, Martin Ian; Langston, Marianne; St. Clair Brown, Adrian
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009054970	A1	20090430	WO 2008-US12015	20081022
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090137579 A1 20090528 US 2008-288596 20081022
PRIORITY APPLN. INFO.: US 2007-12P P 20071023
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI



I

AB The present invention is directed to the compound of formula (I), or a solvate thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound I, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of a compound I, or crystalline forms thereof, for treating a patient suffering from, or subject to, a pathol. condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.

IT 1147862-79-0P 1147862-80-3P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(mesylate salt of an IKK inhibitor)

RN 1147862-79-0 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 1147862-78-9
CMF C26 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 1147862-80-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-, methanesulfonate, compd. with 1-methyl-2-pyrrolidinone (1:1:1) (CA INDEX NAME)

CM 1

CRN 1147862-78-9
CMF C26 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 872-50-4
CMF C5 H9 N O



CM 3

CRN 75-75-2
CMF C H4 O3 S



IT 1147862-78-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(mesylate salt of an IKK inhibitor)
RN 1147862-78-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:519845 CAPLUS Full-text
DOCUMENT NUMBER: 150:501200
TITLE: Salts of N-(6-chloro-9H-pyrido[3,4-b]

indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-morpholinecarboxamide

INVENTOR(S): Hicks, Frederick A.; Cooper, Martin Ian; St. Clair Brown, Adrian

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 56pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009054965	A1	20090430	WO 2008-US12006	20081022
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090131422	A1	20090521	US 2008-288595	20081022
PRIORITY APPLN. INFO.:			US 2007-51P P	20071023

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is directed to the tartrate, monohydrochloride, malonate and p-toluenesulfonate salts of the title compound, or solvates thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the salts, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of the salts, including crystalline forms thereof, for treating a patient suffering from, or subject to, a pathol. condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.

IT 1147862-78-9DP, salts 1147940-42-8P 1147940-43-9P 1147940-44-0P 1147940-45-1P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(salts of N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-morpholinecarboxamide)

RN 1147862-78-9 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1147940-42-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 1147862-78-9
CMF C26 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 1147940-43-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-

[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1147940-44-0 CAPLUS

CN Propanedioic acid, compd. with (3S)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-3-morpholinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 1147862-78-9
CMF C26 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 141-82-2
CMF C3 H4 O4



RN 1147940-45-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 1147862-78-9
CMF C26 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 1147862-78-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(salts of N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-morpholinecarboxamide)
RN 1147862-78-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1147940-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(salts of N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-morpholinecarboxamide)
RN 1147940-46-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-, (2R,3R)-2,3-dihydroxybutanedioate, hydrate (2:1:?) (CA INDEX NAME)

CM 1

CRN 1147862-78-9
CMF C26 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:44944 CAPLUS Full-text
DOCUMENT NUMBER: 150:229351
TITLE: Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen
AUTHOR(S): Lam, Lloyd T.; Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Wright, George; Xu, Weihong; Zhao, Hong; Yu, Xin; Dang, Lenny; Staudt, Louis M.
CORPORATE SOURCE: Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2008), 105(52), 20798-20803
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A subtype of diffuse large B-cell lymphoma (DLBCL), termed activated B-cell-like (ABC) DLBCL, depends on constitutive nuclear factor-κB (NF-κB) signaling for survival. Small mol. inhibitors of IκB kinase β (IKKP), a key regulator of the NF-κB pathway, kill ABC DLBCL cells and hold promise for the treatment of this lymphoma type. We conducted an RNA interference genetic screen to investigate potential mechanisms of resistance of ABC DLBCL cells to IKKβ inhibitors. We screened a library of small hairpin RNAs (shRNAs) targeting 500 protein kinases for shRNAs that would increase the killing of an ABC DLBCL cell line in the presence of a small mol. IKKβ inhibitor. Two independent shRNAs targeting IKKα synergized with the IKKβ inhibitor to kill three different ABC DLBCL cell lines but were not toxic by themselves. Surprisingly, IKKα shRNAs blocked the classical rather than the alternative NF-κB pathway in ABC DLBCL cells, as judged by inhibition of IκBα phosphorylation. IKKα shRNA toxicity was reversed by coexpression of wild-type but not kinase inactive forms of IKKα, suggesting that IKKα may directly phosphorylate IκBα under conditions of IKKβ inhibition. In models of physiol. NF-κB pathway activation by CARD11 or tumor necrosis factor-α, compensatory IKKα activity was also observed with IKKβ inhibition. These results suggest that therapy for ABC DLBCL may be improved by targeting both IKKα and IKKβ, possibly through CARD11 inhibition.

IT 783348-36-7
RL: PAC (Pharmacological activity); BIOL (Biological study)
(MLN 120B; compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by RNA interference sensitization screen)
RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:24556 CAPLUS Full-text
DOCUMENT NUMBER: 150:136620
TITLE: Methods and compositions inducing JNK phosphorylation and tumor apoptosis for combinational anticancer treatments
PATENT ASSIGNEE(S): Yu, Ming, USA
SOURCE: PCT Int. Appl., 92pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009006555	A2	20090108	WO 2008-US69106	20080702
WO 2009006555	A3	20090319		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-929535P P 20070702

AB This invention describes methods and pharmaceutical compns. for combinational cancer treatments that are capable of inducing JNK (c-Jun N-terminal kinase) phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment. The invention is based on two findings: (1) The Cell Proliferation Reagent WST-1 (WST-1r), when combined with DNA-transfection vector pUC19 and an IKK (IκB kinase) inhibitor induces cell death in a synergetic manner in cancer cells and, (2) The effect

of pUC19 vector in the induction of cell death resides in its DNA sequence. Blast anal. of the pUC19 DNA sequence resulted in several short matches to human transcripts and to flanking regions of multiple genes, including TRPC6, SH3PXD2B, C6orf108, TTBK1, MAGI3, and TMEM182. The siRNAs of some of these sequences and the siRNAs against some of above genes were capable of acting as substitutes for the Puc19 for the triple combination treatment. The WST-1 reagent (WST-1r) is composed of WST-1, a tetrazolium salt, and mPMS (1-methoxy-5-methylphenazinium Me sulfate, 1-mPMS), an electron coupling reagent, each representing a class of chems. that can be used to target JNK-ROS-NFκB metabolic pathway in cancer cells. The concentration and the ratio of WST-1 and mPMS could be adjusted and optimized to maintain synergistic induction of cancer cell death while avoiding triggering the direct toxicity by the ROS (reactive oxygen species). It was also shown that apigenin is capable of substituting for the pUC19 DNA transfection and IKK inhibitor, in combination with WST-1 to reach the synergetic induction of cancer cell death. Anticancer effect is Apigenin and WST-1 dose and time dependent and is highly reproducible for multiple different human cancer cell lines.

IT 431898-65-6, PS1145
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IKK inhibitor, combination with; methods and compns. inducing JNK phosphorylation and tumor apoptosis for combinational anticancer treatments)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



L3 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1451541 CAPLUS Full-text

DOCUMENT NUMBER: 150:16131

TITLE: Inhibiting the signs of aging by inhibiting NF-κB activation

INVENTOR(S): Robbins, Paul D.; Niedernhofer, Laura J.

PATENT ASSIGNEE(S): University of Pittsburgh- Of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 57pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008148016	A1	20081204	WO 2008-US64735	20080523

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090075902 A1 20090319 US 2008-126634 20080523

PRIORITY APPLN. INFO.: US 2007-940312P P 20070525

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses methods and compns. for reducing and/or delaying one or more signs of aging which comprise inhibiting NF-κB activation. It is based, at least in part, on the discovery that a peptide which inhibits IKK-β interaction with NEMO, linked to a transducing peptide, inhibits the development of various indicia of senescence in a murine model of aging, Ercc1-1Δ mice.

IT 783348-36-7, ML120B

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NF-κB activation inhibitors for inhibiting signs of aging)

RN 783348-36-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1307396 CAPLUS Full-text

DOCUMENT NUMBER: 149:506107

TITLE: IGFR inhibitor antitumor combination for treatment of cancer therapy

INVENTOR(S): Arnold, Lee D.; Jl, Qun-Sheng; Buck, Elizabeth; Haley, John D.; Mulvihill, Mark J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 131pp., Cont.-in-part of U.S. Ser. No. 787,236.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080267957	A1	20081030	US 2008-72269	20080225
WO 2008018881	A1	20080214	WO 2006-US31433	20060810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2051982	A1	20090429	EP 2006-801288	20060810
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080299113	A1	20081204	US 2006-641346	20061218
US 20080014200	A1	20080117	US 2007-787236	20070413

PRIORITY APPLN. INFO.:	US 2005-752243P	P	20051219
	US 2006-641346	A2	20061218
	US 2007-787236	A2	20070413
	WO 2006-US31433	W	20060810

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 149:506107
GI



I

AB Methods and compns. for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound I, with or without addnl. agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by formula I where X1, X2, and X5=N or -C-(E1), etc.; X3, X4, X6, and X7=N or C; R1=absent, C0-C10alkyl, etc.; E1=halogen, CF3, etc.; and Q1 is II where X11,X12,X13,X14,X15, and X16=N, etc.; and G1=halogen, CF3, etc. Imidazopyrazine derivs. inhibiting IGF-1R potentiated EGF-1R inhibitor Tarceva-induced apoptosis in solid tumor cells.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IGFR inhibitor antitumor combination for treatment of cancer)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX

NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:976445 CAPLUS Full-text
DOCUMENT NUMBER: 150:89875
TITLE: Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-κB Pathways
AUTHOR(S): Liu, Dingxie; Xing, Mingzhao
CORPORATE SOURCE: Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD, USA
SOURCE: Thyroid (2008), 18(8), 853-864
CODEN: THYRER; ISSN: 1050-7256
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We recently demonstrated inhibition of thyroid cancer cells by the MEK inhibitor CI-1040. The objective of this study was to use a potent new-generation MEK inhibitor PD0325901 to further investigate the therapeutic potential of specifically targeting MEK in the MAP kinase pathway for thyroid cancer. We examined the effects of PD0325901 on a variety of cellular and mol. activities of thyroid cancer cell lines with distinct genotypes. PD0325901 remarkably inhibited MAP kinase pathway signaling in the thyroid cancer cells tested. It potently inhibited cell proliferation (IC50 = 0.059-0.783 μM) and arrested cell cycle at the G0/G1 phase of cells harboring BRAF or RAS mutations but not cells harboring wild-type alleles or the RET/PTC1 rearrangement. Synergistic inhibitory effects were observed when PD0325901 was combined with phosphatidylinositol 3-kinase (PI3K) or NF-κB pathway inhibitors in most cells, including the RET/PTC1-harboring cells. PD0325901 could inhibit invasion and anchorage-independent growth of thyroid cancer cells independently of the type of genetic alterations. This compound did not seem to have significant proapoptotic effects, however. The MEK inhibitor PD0325901 has a wide range of potent inhibitory effects on thyroid cancer cells, some of which seemed to be genotype-selective, consistent with the results previously observed with an early-generation MEK inhibitor, CI-1040. The data provide further evidence that targeted inhibition of MEK may be therapeutically effective for thyroid cancer, particularly if the PI3K and NF-κB pathways are concurrently inhibited.

IT 431898-65-6, PS1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PD0325901 showed synergistic inhibitory effect when combined with LY294002 or PS1145 in human thyroid cancer cell)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:770584 CAPLUS Full-text

DOCUMENT NUMBER: 149:70442

TITLE: Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and β-agonists for the treatment of pulmonary inflammation and bronchoconstriction

INVENTOR(S): Baker, William R.; Stasiak, Marcin; Swaminathan, Sundaramoorthi

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 95pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076265	A1	20080626	WO 2007-US25361	20071212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007334541	A1	20080626	AU 2007-334541	20071212
CA 2670730	A1	20080626	CA 2007-2670730	20071212

EP 2125841 A1 20091202 EP 2007-853345 20071212
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR
IN 2009KN02012 A 20090619 IN 2009-KN2012 20090527
PRIORITY APPLN. INFO.: US 2006-874543P P 20061213
WO 2007-US25361 W 20071212
OTHER SOURCE(S): MARPAT 149:70442
GI



I

AB A mutual prodrug, I (X = quaternizable moiety; L = bond, CH2O, etc.; R = C1-12 hydroxyaminoalkyl, hetero (un)substituted arylalkyl, etc.; R1R2R3X = muscarinic receptor antagonist or its prodrug linking the parent MRA mol. to X) and pharmaceutical salts thereof, of an AISTM and a β-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between about 1 to 5 μ, produced by nebulization or by dry powder inhaler.

IT 1034189-78-0P 1034189-79-1P 1034189-80-4P
1034189-81-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for treatment of pulmonary inflammation and bronchoconstriction)

RN 1034189-78-0 CAPLUS

CN 9H-Pyrido[3,4-b]indolium, 6-chloro-2-[[4-[1-hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(phosphonooxy)phenyl]methyl]-7-methoxy-8-[[(2-methyl-3-pyridinyl)carbonyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 1034189-79-1 CAPLUS
CN 9H-Pyrido[3,4-b]indolium, 6-chloro-2-[[4-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-(phosphonooxy)phenyl]methyl]-7-methoxy-8-[[(2-methyl-3-pyridinyl)carbonyl]amino]- (CA INDEX NAME)



RN 1034189-80-4 CAPLUS
CN 9H-Pyrido[3,4-b]indolium, 6-chloro-2-[[4-[1-hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-[(phosphonooxy)methoxy]phenyl]methyl]-7-methoxy-8-[[(2-methyl-3-pyridinyl)carbonyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 1034189-81-5 CAPLUS
CN 9H-Pyrido[3,4-b]indolium, 6-chloro-2-[[4-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-[(phosphonooxy)methoxy]phenyl]methyl]-7-methoxy-8-[[(2-methyl-3-pyridinyl)carbonyl]amino]- (CA INDEX NAME)



IT 783348-36-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for treatment of pulmonary inflammation and bronchoconstriction)
RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:431542 CAPLUS Full-text
DOCUMENT NUMBER: 148:377372
TITLE: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
AUTHOR(S): Lam, Lloyd T.; Wright, George; Davis, R. Eric; Lenz, Georg; Farinha, Pedro; Dang, Lenny; Chan, John W.; Rosenwald, Andreas; Gascoyne, Randy D.; Staudt, Louis M.
CORPORATE SOURCE: Metabolism Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA
SOURCE: Blood (2008), 111(7), 3701-3713
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The activated B cell-like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL) is characterized by constitutive activation of the nuclear factor-κB (NF-κB) pathway. In this study, we showed that the NF-κB pathway induced the expression of the cytokines interleukin (IL)-6 and IL-10 in ABC DLBCL cell lines, which also have high levels of total and phosphorylated signal transducer and activator of transcription (STAT) 3 protein, suggesting autocrine signaling. Using RNA interference for STAT3, we defined a gene expression signature of IL-6 and IL-10 signaling through STAT3. Based on this signature, we constructed a mol. predictor of STAT3 signaling that defined a subset of ABC DLBCL tumors with high expression of STAT3, IL-6, and/or IL-10 and their downstream targets. Although the STAT3-high and STAT3-low subsets had equivalent expression of genes that distinguish ABC DLBCL from germinal center B cell-like DLBCL, STAT3-high ABC DLBCLs had higher expression of signatures that reflected NF-κB activity, proliferation, and glycolysis. A small-mol. inhibitor of Janus kinase signaling, which blocked STAT3 signature expression, was toxic only for ABC DLBCL lines and synergized with an inhibitor of NF-κB signaling. These findings suggest that the biol. interplay between the STAT3 and NF-κB pathways may be exploited for the treatments of a subset of ABC DLBCLs.

IT 783348-36-7, MLN 120B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin-6 and interleukin-10 signaling through STAT3 and

NF-κB in diffuse large B-cell lymphoma and new strategies for therapy)

RN 783348-36-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:74166 CAPLUS Full-text

DOCUMENT NUMBER: 148:135995

TITLE: Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents

INVENTOR(S): Arnold, Lee D.; Ji, Qun-Sheng; Mulvihill, Mark Joseph

PATENT ASSIGNEE(S): OSI Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 225 pp., Cont.-in-part of U.S. Ser. No. 641,346, abandoned.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080014200	A1	20080117	US 2007-787236	20070413
WO 2008018881	A1	20080214	WO 2006-US31433	20060810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2051982	A1	20090429	EP 2006-801288	20060810
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

US 20080299113	A1	20081204	US 2006-641346		20061218
US 20080267957	A1	20081030	US 2008-72269		20080225
PRIORITY APPLN. INFO.:			US 2005-752243P	P	20051219
			US 2006-641346	B2	20061218
			WO 2006-US31433	W	20060810
			US 2007-787236	A2	20070413

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:135995

AB The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anti-cancer agent and an IGF1R inhibitor compound, presented here, in combination, with or without addnl. agents or treatments, such as other anti-cancer drugs or radiation therapy.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined treatment with bicyclic ring substituted heterobicyclic protein kinase inhibitor and anticancer agents)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



L3 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1355768 CAPLUS Full-text

DOCUMENT NUMBER: 148:232472

TITLE: The selectivity of protein kinase inhibitors: a further update

AUTHOR(S): Bain, Jenny; Plater, Lorna; Elliott, Matt; Shpiro, Natalia; Hastie, C. James; McLauchlan, Hilary; Klevernic, Iva; Arthur, J. Simon C.; Alessi, Dario R.; Cohen, Philip

CORPORATE SOURCE: Division of Signal Transduction Therapy, College of Life Sciences, University of Dundee, Scotland, DD1 5EH, UK

SOURCE: Biochemical Journal (2007), 408(3), 297-315
CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The specificities of 65 compds. reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein

kinases. On the basis of this information, the effects of compds. that we have studied in cells and other data in the literature, we recommend the use of the following small-mol. inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiol. roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)-raptor (regulatory associated protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor. We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro. The results have further emphasized the need for considerable caution in using small-mol. inhibitors of protein kinases to assess the physiol. roles of these enzymes. Despite being used widely, many of the compds. that we analyzed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.

IT 431898-65-6, PS 1145
RL: ARG (Analytical reagent use); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(selectivity of protein kinase inhibitors)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 206 THERE ARE 206 CAPLUS RECORDS THAT CITE THIS RECORD (207 CITINGS)

REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1062479 CAPLUS Full-text

DOCUMENT NUMBER: 147:392042

TITLE: Continuous delivery of D-luciferin by implanted microosmotic pumps enables true real-time bioluminescence imaging of luciferase activity in vivo

AUTHOR(S): Gross, Shimon; Abraham, Ute; Prior, Julie L.; Herzog, Erik D.; Piwnica-Worms, David

CORPORATE SOURCE: Molecular Imaging Center, Mallinckrodt Institute of

Radiology, Department of Molecular Biology and Pharmacology, and Department of Biology, Washington University in St. Louis, St. Louis, MO, USA
SOURCE: Molecular Imaging (2007), 6(2), 121-130
CODEN: MIOMBP; ISSN: 1535-3508
PUBLISHER: BC Decker Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Bioluminescence imaging (BLI) of luciferase reporters in small animal models offers an attractive approach to monitor regulation of gene expression, signal transduction, and protein-protein interactions, as well as following tumor progression, cell engraftment, infectious pathogens, and target-specific drug action. Conventional BLI can be repeated within the same animal after bolus reinjections of a bioluminescent substrate. However, intervals between image acquisitions are governed by substrate pharmacokinetics and excretion, therefore restricting temporal resolution of reinjection protocols to the order of hours, limiting analyses of processes in vivo with short time consts. To eliminate these constraints, we examined use of implanted micro-osmotic pumps for continuous, long-term delivery of bioluminescent substrates. Pump-assisted D-luciferin delivery enabled BLI for ≥ 7 days from a variety of luciferase reporters. Pumps allowed direct repetitive imaging at < 5-min intervals of the pharmacodynamics of proteasome- and IKK-inhibiting drugs in mice bearing tumors stably expressing ubiquitin-firefly luciferase or IκBα-firefly luciferase fusion reporters. Circadian oscillations in the olfactory bulbs of transgenic rats expressing firefly luciferase under the control of the period1 promoter also were temporally resolved over the course of several days. We conclude that implanted pumps provide reliable, prolonged substrate delivery for high temporal resolution BLI, traversing complications of repetitive substrate injections.
IT 431898-65-6, PS-1145
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(continuous delivery of D-luciferin by implanted microosmotic pump enable real-time BLI of pharmacol. of IκBα kinase inhibiting PS-1145 in mouse bearing firefly luciferase or IκBα-firefly luciferase expressing human cervical cancer)
RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1060852 CAPLUS Full-text
DOCUMENT NUMBER: 147:378396
TITLE: nf-kb activation inhibitors for treating muscular wasting diseases
INVENTOR(S): Guttridge, Denis C.; Baldwin, Albert S.
PATENT ASSIGNEE(S): Theralogics, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007106884	A2	20070920	WO 2007-US64057	20070315
WO 2007106884	A3	20080529		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2646316	A1	20070920	CA 2007-2646316	20070315
US 20070225315	A1	20070927	US 2007-686623	20070315
EP 2001455	A2	20081217	EP 2007-758595	20070315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-782427P P 20060315
WO 2007-US64057 W 20070315
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment a nuclear factor kappa B (NF-KB) activation inhibitor capable of blocking the activation of NF-KB. Administration of peptides comprised of a Nuclear Factor Essential (NEMO) binding domain to a mouse model of Duchenne muscular dystrophy significantly increased diaphragm contractions.

IT 431898-65-6 783348-36-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nf-kb activation inhibitors for treating muscular wasting diseases)
RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



L3 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:930813 CAPLUS Full-text
DOCUMENT NUMBER: 148:992
TITLE: Bortezomib inhibits human osteoclastogenesis
AUTHOR(S): von Metzler, I.; Krebbel, H.; Hecht, M.; Manz, R. A.; Fleissner, C.; Mieth, M.; Kaiser, M.; Jakob, C.; Sterz, J.; Kleeberg, L.; Heider, U.; Sezer, O.
CORPORATE SOURCE: Department of Hematology and Oncology, Charite - Universitaetsmedizin Berlin, Berlin, Germany
SOURCE: Leukemia (2007), 21(9), 2025-2034
CODEN: LEUKED; ISSN: 0887-6924
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In multiple myeloma, the overexpression of receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL) leads to the induction of NF-κB and activator protein-1 (AP-1)-related osteoclast activation and enhanced bone resorption. The purpose of this study was to examine the mol. and functional effects of proteasome inhibition in RANKL-induced osteoclastogenesis. Furthermore, we aimed to compare the outcome of proteasome vs. selective NF-κB inhibition using bortezomib (PS-341) and I-κB kinase inhibitor PS-1145. Primary human osteoclasts were derived from CD14+ precursors in presence of RANKL and macrophage colony-stimulating factor (M-CSF). Both bortezomib and PS-1145 inhibited osteoclast differentiation in a dose- and time-dependent manner and furthermore, the bone resorption activity of osteoclasts. The mechanisms of action involved in early osteoclast differentiation were found

to be related to the inhibition of p38 mitogen-activated protein kinase pathways, whereas the later phase of differentiation and activation occurred due to inhibition of p38, AP-1 and NF-κB activation. The AP-1 blockade contributed to significant reduction of osteoclastic vascular endothelial growth factor production In conclusion, our data demonstrate that proteasomal inhibition should be considered as a novel therapeutic option of cancer-induced lytic bone disease.

IT 431898-65-6, PS-1145
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I-κB kinase inhibitor PS-1145 inhibited osteoclast differentiation in dose- and time-dependent manner and bone resorption activity of human osteoclast)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:749003 CAPLUS Full-text

DOCUMENT NUMBER: 147:314170

TITLE: Nuclear factor-κB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer

AUTHOR(S): Singh, Sindhu; Shi, Qian; Bailey, Shannon T.; Palczewski, Marek J.; Pardee, Arthur B.; Iglehart, J. Dirk; Biswas, Debajit K.

CORPORATE SOURCE: Departments of Cancer Biology and Medical Oncology, Dana-Farber Cancer Institute, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA

SOURCE: Molecular Cancer Therapeutics (2007), 6(7), 1973-1982
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nuclear factor-κB (NF-κB), a transcription factor with pleiotropic effects, is a downstream mediator of growth signaling in estrogen receptor (ER)-neg. and erbB family particularly erbB2 (HER-2/neu) receptor-pos. cancer. We previously reported activation of NF-κB in ER-neg. breast cancer cells and breast tumor specimens, but the consequence of inhibiting NF-κB activation in

this subclass of breast cancer has not been shown. In this study, we investigated the role of NF-κB activation by studying the tumorigenic potential of cells expressing genetically manipulated, inducible, dominant-neg. inhibitory κB kinase (IKKβ) in xenograft tumor model. Conditional inhibition of NF-κB activation by the inducible expression of dominant-neg. IKKβ simultaneously blocked cell proliferation, reinstated apoptosis, and dramatically blocked xenograft tumor formation. Secondly, the humanized anti-erbB2 antibody trastuzumab (Herceptin) and the specific IKK inhibitor NF-κB essential modifier-binding domain peptide both blocked NF-κB activation and cell proliferation and reinstated apoptosis in two ER-neg. and erbB2-pos. human breast cancer cell lines that are used as representative model systems. Combinations of these two target-specific inhibitors synergistically blocked cell proliferation at concns. that were singly ineffective. Inhibition of NF-κB activation with two other low mol. weight compds., PS1145 and PS341, which inhibited IKK activity and proteasome-mediated phosphorylated inhibitory κB protein degradation, resp., blocked erbB2-mediated cell growth and reversed antiapoptotic machinery. These results implicate NF-κB activation in the tumorigenesis and progression of ER-neg. breast cancer. It is postulated that this transcription factor and its activation cascade offer therapeutic targets for erbB2-pos. and ER-neg. breast cancer.

IT 431898-65-6, PS1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nuclear factor-κB signaling as mol. therapeutic target for estrogen receptor-neg. and epidermal growth factor receptor family receptor-pos. human breast cancer)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:513294 CAPLUS Full-text
DOCUMENT NUMBER: 146:475302
TITLE: Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IκB kinase inhibitors
AUTHOR(S): Newton, Robert; Holden, Neil S.; Catley, Matthew C.; Oyelusi, Wale; Leigh, Richard; Proud, David; Barnes, Peter J.

CORPORATE SOURCE: Respiratory Research Group, Departments of Cell Biology and Anatomy, Physiology and Biophysics, and Medicine, University of Calgary, Calgary, AB, Can.
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 321(2), 734-742
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The airway epithelium is critical in the pathogenesis of chronic inflammatory diseases, such as asthma and chronic obstructive pulmonary disease, and, by expressing numerous inflammatory genes, plays a prominent role in disease exacerbations. Since inflammatory gene expression often involves the transcription factor nuclear factor (NF)-κB, this signaling pathway represents a site for anti-inflammatory intervention. As the airway epithelium is targeted by inhaled therapeutic agents, for example corticosteroids, human A549 pulmonary cells and primary human bronchial epithelial (HBE) cells were selected to evaluate inhibitor of κB kinase (IKK) inhibitors. In A549 cells, interleukin (IL)-1β and tumor necrosis factor (TNF) α increased phosphorylation of IκBα, and this was followed by loss of IκBα, induction of NF-κB DNA binding, and the induction of NF-κB-dependent transcription. These events were repressed by the IKK-selective inhibitors, PS-1145 [N-(6-chloro-9H-β-carbolin-8- ly)nicotinamide] and ML120B [N-(6-chloro-7-methoxy-9H-β-carbolin-8- yl)-2-methylnicotinamide]. Inhibition of NF-κB-dependent transcription was concentration-dependent and correlated with loss of intercellular adhesion mol. (ICAM)-1 expression. Similarly, IL-1β- and TNFα-induced expression of IL-6, IL-8, granulocyte macrophage-colony-stimulating factor (GM-CSF), regulated and activation normal T cell expressed and secreted (RANTES), growth-related oncogene α, and monocyte chemotactic protein-1 (MCP-1) was also significantly repressed. Likewise, PS-1145 and ML120B profoundly reduced NF-κB-dependent transcription induced by IL-1β and TNFα in primary HBE cells. Parallel effects on ICAM-1 expression and a significant repression of IL-8 release were observed In contrast, the corticosteroid, dexamethasone, was without effect on NF-κB-dependent transcription or the expression of ICAM-1. The above data provide strong support for an anti-inflammatory effect of IKK2 inhibitors acting on the pulmonary epithelium and suggest that such compds. may prove beneficial in situations where traditional corticosteroid therapies prove inadequate.
IT 431898-65-6, PS-1145 783348-36-7, ML120B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(repression of inflammatory gene expression in human pulmonary epithelial cells by small-mol. IκB kinase inhibitors)
RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:152107 CAPLUS Full-text
DOCUMENT NUMBER: 146:371811
TITLE: Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis
AUTHOR(S): Izmailova, Elena S.; Paz, Nancy; Alencar, Herlen; Chun, Miyoung; Schopf, Lisa; Hepperle, Michael; Lane, Joan H.; Harriman, Geraldine; Xu, Yajun; Ocain, Timothy; Weissleder, Ralph; Mahmood, Umar; Healy, Aileen M.; Jaffee, Bruce
CORPORATE SOURCE: Merrimack Pharmaceuticals, Cambridge, MA, USA
SOURCE: Arthritis & Rheumatism (2007), 56(1), 117-128
CODEN: ARHEAW; ISSN: 0004-3591
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: The NF-κB signaling pathway promotes the immune response in rheumatoid arthritis (RA) and in rodent models of RA. NF-κB activity is regulated by the IKK-2 kinase during inflammatory responses. To elucidate how IKK-2 inhibition suppresses disease development, we used a combination of in vivo imaging, transcription profiling, and histopathol. technologies to study mice with antibody-induced arthritis. Methods: ML120B, a potent, small mol.

inhibitor of IKK-2, was administered to arthritic animals, and disease activity was monitored. NF-κB activity in diseased joints was quantified by in vivo imaging. Quant. reverse transcriptase-polymerase chain reaction was used to evaluate gene expression in joints. Protease-activated near-IR fluorescence (NIRF) in vivo imaging was applied to assess the amts. of active proteases in the joints. Results: Oral administration of ML120B suppressed both clin. and histopathol. manifestations of disease. In vivo imaging demonstrated that NF-κB activity in inflamed arthritic paws was inhibited by ML120B, resulting in significant suppression of multiple genes in the NF-κB pathway, i.e., KC, epithelial neutrophil-activating peptide 78, JE, intercellular adhesion mol. 1, CD3, CD68, tumor necrosis factor α, interleukin-1β, interleukin-6, inducible nitric oxide synthase, cyclooxygenase 2, matrix metalloproteinase 3, cathepsin B, and cathepsin K. NIRF in vivo imaging demonstrated that ML120B treatment dramatically reduced the amount of active proteases in the joints. Conclusion: Our data demonstrate that IKK-2 inhibition in the murine model of antibody-induced arthritis suppresses both inflammation and joint destruction. In addition, this study highlights how gene expression profiling can facilitate the identification of surrogate biomarkers of disease activity and treatment response in an exptl. model of arthritis.

IT 783348-36-7, ML120B
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ML120B reduced antibody-induced rheumatoid arthritis by suppressing multiple genes in nuclear factor κB pathway and degradation of bone and cartilage in mouse)

RN 783348-36-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1252828 CAPLUS Full-text

DOCUMENT NUMBER: 146:20338

TITLE: NFκB pathway inhibitors for treatment of muscular dystrophy

INVENTOR(S): Carlson, C. George; Samadi, Abbas

PATENT ASSIGNEE(S): A. T. Still University of Health Sciences, USA

SOURCE: PCT Int. Appl., 100pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127930	A2	20061130	WO 2006-US20301	20060524
WO 2006127930	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006249851	A1	20061130	AU 2006-249851	20060524
CA 2613337	A1	20061130	CA 2006-2613337	20060524
US 20060280812	A1	20061214	US 2006-439714	20060524
EP 1888060	A2	20080220	EP 2006-771212	20060524
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.:

US 2005-684504P	P	20050524
US 2006-762394P	P	20060126
WO 2006-US20301	W	20060524

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Compns. and methods for treatment of individuals diagnosed with a dystrophin deficiency are disclosed. In particular, inhibitors of nuclear factor kappa B (NFκB) activation, such as pyrrolidine dithiocarbamate (PDTC), have been shown to prevent and reverse muscle damage in animals lacking dystrophin. Such compns. and methods are useful in the treatment of individuals with muscular dystrophy. NFκB pathway inhibitor, sulfasalazine, significantly improved the resting membrane potential in dystrophic triangularis sterni muscles providing support for it's use in treatment of Duchenne muscular dystrophy.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NFκB pathway inhibitors for treatment of muscular dystrophy)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1189144 CAPLUS Full-text
DOCUMENT NUMBER: 146:161336
TITLE: IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis
AUTHOR(S): Schopf, Lisa; Savinainen, Anneli; Anderson, Karen; Kujawa, Julie; DuPont, Michelle; Silva, Matthew; Siebert, Elizabeth; Chandra, Sudeep; Morgan, Jennifer; Gangurde, Pranoti; Wen, Danyi; Lane, Joan; Xu, Yajun; Hepperle, Michael; Harriman, Geraldine; Ocain, Timothy; Jaffee, Bruce
CORPORATE SOURCE: Millennium Pharmaceuticals, Cambridge, MA, USA
SOURCE: Arthritis & Rheumatism (2006), 54(10), 3163-3173
CODEN: ARHEAW; ISSN: 0004-3591
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective. The IKK complex regulates NF-κB activation, an important pathway implicated in the rheumatoid arthritis (RA) disease process. This study was undertaken to assess the efficacy of N-(6-chloro-7-methoxy-9H-β-carbolin-8-yl)-2-methylnicotinamide (ML120B), a potent and selective small mol. inhibitor of IKKβ. Methods. Polyarthritis was induced in rats by injection of Freund's complete adjuvant into the hind footpad. ML120B was administered orally twice daily, either prophylactically or therapeutically. Paw vols. and body wts. were measured every 2-3 days throughout the study. We assessed bone erosions by several methods: histol. evaluation, quant. micro-computed tomog. (micro-CT) imaging anal., and measurement of type I collagen fragments in the serum. Quant. polymerase chain reaction was used to evaluate expression of mRNA for genes related to inflammation and to bone and cartilage integrity. Results. Oral administration of ML120B inhibited paw swelling in a dose-dependent manner (median effective dosage 12 mg/kg twice daily) and offered significant protection against arthritis-induced weight loss as well as cartilage and bone erosion. We were able to directly demonstrate that NF-κB activity in arthritic joints was reduced after ML120B administration. Also, we observed that down-regulation of the NF-κB pathway via IKKβ inhibition dampened the chronic inflammatory process associated with rat adjuvant-induced arthritis. Conclusion. The results of the present study suggest that IKKβ inhibition is an effective therapeutic approach to treat both the inflammation and the bone/cartilage destruction observed in RA. Methods for the determination of serum markers for bone and cartilage destruction, as well as micro-CT anal., may aid in predicting and evaluating the therapeutic efficacy of IKKβ inhibition therapy in humans.

IT 783348-36-7, ML120B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IKKβ inhibition protects against bone and cartilage destruction in rat model of rheumatoid arthritis)

RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1028772 CAPLUS Full-text
DOCUMENT NUMBER: 146:74798
TITLE: MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo
AUTHOR(S): Hideshima, Teru; Neri, Paola; Tassone, Pierfranchesco; Yasui, Hiroshi; Ishitsuka, Kenji; Raje, Noopur; Chauhan, Dharminder; Podar, Klaus; Mitsiades, Constantine; Dang, Lenny; Munshi, Nikhil; Richardson, Paul; Schenkein, David; Anderson, Kenneth C.
CORPORATE SOURCE: Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
SOURCE: Clinical Cancer Research (2006), 12(19), 5887-5894
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The purpose of this study is to delineate the biol. significance of IκB kinase (IKK) {szligbeta} inhibition in multiple myeloma cells in the context of bone marrow stromal cells (BMSC) using a novel IKK{szligbeta} inhibitor MLN120B. Growth-inhibitory effect of MLN120B in multiple myeloma cells in the presence of cytokines [interleukin-6 (IL-6) and insulin-like growth factor-I (IGF-1)], conventional agents (dexamethasone, melphalan, and doxorubicin), or BMSC was assessed in vitro. In vivo anti-multiple myeloma activity of MLN120B was evaluated in severe combined immunodeficient (SCID)-hu model. MLN120B inhibits both baseline and tumor necrosis factor-α-induced nuclear factor-κB activation, associated with down-regulation of IκBα and p65 nuclear factor-κB phosphorylation. MLN120B triggers 25% to 90% growth inhibition in a dose-dependent fashion in multiple myeloma cell lines and significantly augments tumor necrosis factor-α-induced cytotoxicity in MM.1S cells. MLN120B augments growth inhibition triggered by doxorubicin and melphalan in both RPMI 8226 and IL-6-dependent INA6 cell lines. Neither IL-6 nor IGF-1 overcomes the growth-inhibitory effect of MLN120B. MLN120B inhibits constitutive IL-6 secretion by BMSCs by 70% to 80% without affecting viability. Importantly, MLN120B almost completely blocks stimulation of MM.1S, U266, and INA6 cell growth, as well as IL-6 secretion from BMSCs, induced by multiple myeloma cell adherence to BMSCs. MLN120B overcomes the protective effect of BMSCs against conventional (dexamethasone) therapy. Our data show that the novel IKK{szligbeta} inhibitor MLN120B induces growth inhibition of multiple myeloma cells in SCID-

hu mouse model. These studies provide the framework for clin. evaluation of MLN120B, alone and in combined therapies, trials of these novel agents to improve patient outcome in multiple myeloma.

IT 783348-36-7, MLN 120B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IκB kinase β inhibitor MLN120B induced growth inhibition of human multiple myeloma cells in severe combined immunodeficient-hu mouse model)

RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:990248 CAPLUS Full-text
DOCUMENT NUMBER: 147:936
TITLE: Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent orostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
AUTHOR(S): Domingo-Domenech, Josep; Oliva, Cristina; Rovira, Ana; Codony-Servat, Jordi; Bosch, Marta; Filella, Xavier; Montagut, Clara; Tapia, Marian; Campas, Clara; Dang, Lenny; Rolfe, Mark; Ross, Jeffrey S.; Gascon, Pere; Albanell, Joan; Mellado, Begona
CORPORATE SOURCE: Department of Medical Oncology and Laboratory of Experimental Oncology, Institut Clinic Malalties Hemato-Oncologiques, University of Barcelona, Barcelona, Spain
SOURCE: Clinical Cancer Research (2006), 12(18), 5578-5586
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To investigate whether nuclear factor κB (NF-κB)/interleukin 6 (IL-6) was linked to docetaxel response in human prostate cancer cell lines, and whether inhibition of NF-κB sensitized tumor cells to docetaxel. We also aimed to correlate IL-6 (as a surrogate marker of NF-κB) and docetaxel response in

hormone-independent prostate cancer (HIPC) patients. Hormone-dependent (LNCaP) and hormone-independent (PC-3 and DU-145) prostate cancer cell lines were exposed to docetaxel alone or combined with the NF-κB inhibitor PS-1145 (an inhibitor of IκB kinase-2). Effects of dose, exposure time, and schedule dependence were assessed. Activation of NF-κB was assayed by electrophoresis mobility shift assay and luciferase reporter assay, IL-6 levels by ELISA, and cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle and apoptosis were assessed by fluorescence-activated cell sorting anal. Apoptosis was also measured by detection of cleavage of poly(ADP-ribose) polymerase. In patients with metastatic HIPC receiving docetaxel-based chemotherapy, IL-6 serum levels were assayed before chemotherapy and every 3 to 4 wk thereafter. PC-3 and DU-145 cells had higher NF-κB activity, secreted more IL-6, and were more resistant to docetaxel than LNCaP cells. NF-κB activity was induced by docetaxel. Cotreatment with docetaxel and PS-1145 prevented docetaxel-induced NF-κB activation, reduced IL-6 production, and increased docetaxel effects on cell viability in PC-3 and DU-145 cells but not in LNCaP. Synergism with docetaxel and PS-1145, as assayed by median-effect principle, was observed in DU-145 and PC-3. In HIPC patients, pretreatment IL-6 serum levels correlated to prostate-specific antigen (PSA) response: median IL-6 level was 10.8 ± 9.5 pg/mL in PSA responders vs. 36.7 ± 20.8 pg/mL (P = 0.006) in nonresponders. A PSA response was also linked to a decline in IL-6 levels during treatment. Median overall survival was 6.8 mo in patients with high IL-6 vs. 16.6 mo in those with low IL-6 (P = 0.0007). On multivariate anal., pretreatment IL-6 (P = 0.05) was an independent prognostic factor for time to disease progression and survival. Inhibition of NF-κB emerges as an attractive strategy to enhance docetaxel response in prostate cancer. The interest of this view is further supported by a significant association between high IL-6 in sera of HIPC patients and decreased response to docetaxel.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nuclear factor-κB inhibition enhanced docetaxel antitumor activity in hormone-independent prostate cancer cell line while high interleukin 6 predicted resistance to docetaxel and survival in hormone-independent prostate cancer patient)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT:	20	THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
REFERENCE COUNT:	25	THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:968421 CAPLUS Full-text
DOCUMENT NUMBER: 146:6282
TITLE: Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
AUTHOR(S): Khanbolooki, Sanaz; Nawrocki, Steffan T.; Arumugam, Thiruvengadam; Andtbacka, Robert; Pino, Maria S.; Kurzrock, Razelle; Logsdon, Craig D.; Abbruzzese, James L.; McConkey, David J.
CORPORATE SOURCE: M. D. Anderson Cancer Center, Departments of Cancer Biology and Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas and Division of Medical Oncology, University of Texas, Houston, TX, USA
SOURCE: Molecular Cancer Therapeutics (2006), 5(9), 2251-2260
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Although it displays promising activity in other tumor models, the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on human pancreatic cancer cells have not been comprehensively explored. We report that a majority of human pancreatic cancer cell lines (seven of nine) underwent apoptosis when they were exposed to recombinant human TRAIL in vitro. Characterization of surface TRAIL receptors by fluorescence-activated cell sorting showed that TRAIL-resistant cells (Panc-1 and HS766T) expressed lower levels of DR4 and DR5 than did TRAIL-sensitive cells. The proteasome inhibitor bortezomib (PS-341, Velcade) further increased TRAIL responsiveness in the TRAIL-sensitive cells and synergized with TRAIL to reverse resistance in Panc-1 and HS776T cells. The effects of bortezomib were mimicked by transfection with a small interfering RNA construct specific for the p65 subunit of nuclear factor-κB (NF-κB) or exposure to a selective chemical inhibitor of IKK (PS-1145). Silencing IκBα prevented TRAIL sensitization by PS-1145, confirming that IκBα mediated the effects of PS-1145. NF-κB inhibition resulted in down-regulation of BCL-XL and XIAP, and silencing either restored TRAIL sensitivity in TRAIL-resistant cells. Finally, therapy with TRAIL plus PS-1145 reversed TRAIL resistance in vivo to produce synergistic growth inhibition in orthotopic Panc-1 tumors. Together, our results show that NF-κB inhibits TRAIL-induced apoptosis in human pancreatic cancer cells and suggest that combination therapy with TRAIL and NF-κB inhibitors, such as bortezomib, PS-1145, or curcumin, should be considered as a possible treatment strategy in patients with pancreatic cancer.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NF-κB maintains TRAIL resistance in human pancreatic cancer cells)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:960790 CAPLUS Full-text
DOCUMENT NUMBER: 147:235039
TITLE: Synthesis of C-14 and C-13, H-2-labeled IKK inhibitor: [14C] and [13C4,D3]-N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide
AUTHOR(S): Li, Yuexian; Plesescu, Mihaela; Prakash, Shimoga R.
CORPORATE SOURCE: Department of Drug Metabolism and Pharmacokinetics, Radiochemistry Group, Millennium Pharmaceuticals, Cambridge, MA, 02139, USA
SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (2006), 49(9), 789-799
CODEN: JLCRD4; ISSN: 0362-4803
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:235039

AB [14C]-N-(6-Chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide, an IKK inhibitor [i.e., kinase (phosphorylating) IκB protein] was synthesized from [14C]-barium carbonate in two steps in an overall radiochem. yield of 41%. The intermediate, [carboxy-14C]-2-methylnicotinic acid [i.e., 2-methyl-3-pyridinecarboxylic-14C acid] was prepared by lithiation and carboxylation of 3-bromo-2-methylpyridine. [13C4,D3]-N-(6-chloro-7-methoxy-9H-pyrido [3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide was synthesized from Et [1,2,3,4-13C4]acetoacetate and [D4]-methanol in six steps in an overall yield of 2%. [13C4]-2-methylnicotic acid, was prepared by condensation of Et [13C4]-3-aminocrotonate and acrolein, followed by hydrolysis with lithium hydroxide.

IT 783348-36-7P, ML 120B 945482-99-5P
945483-05-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation 14C-labeled, 13C-labeled and 2H-labeled N-[chloro(methoxy)pyrido[3,4-b]indolyl)(methyl)pyridinecarboxamide derivs.)
RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 945482-99-5 CAPLUS
CN 3-Pyridinecarboxamide-14C, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 945483-05-6 CAPLUS
CN 3-Pyridine-2,3-13C2-carboxamide-13C, N-[6-chloro-7-(methoxy-d3)-9H-pyrido[3,4-b]indol-8-yl]-2-(methyl-13C)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:778034 CAPLUS Full-text
DOCUMENT NUMBER: 145:241370
TITLE: Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle
AUTHOR(S): Catley, Matthew C.; Sukkar, Maria B.; Chung, K. Fan; Jaffee, Bruce; Liao, Sha-Mei; Coyle, Anthony J.; Haddad, El-Bdaoui; Barnes, Peter J.; Newton, Robert
CORPORATE SOURCE: National Heart & Lung Institute, Imperial College London, London, UK
SOURCE: Molecular Pharmacology (2006), 70(2), 697-705
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Asthma and chronic obstructive pulmonary disease (COPD) are characterized by chronic airway inflammation. However, because patients with COPD and certain patients with asthma show little or no therapeutic benefit from existing corticosteroid therapies, there is an urgent need for novel anti-inflammatory strategies. The transcription factor nuclear factor-κB (NF-κB) is central to inflammation and is necessary for the expression of numerous inflammatory genes. Proinflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor (TNF)-α, activate the IκB kinase complex (IKK) to promote the degradation of inhibitory IκB proteins and activate NF-κB. This pathway and, in particular, the main IκB kinase, IKK2, are now considered prime targets for novel anti-inflammatory drugs. Therefore, we have used adenoviral overexpression to demonstrate NF-κB and IKK2 dependence of key inflammatory genes, including intercellular adhesion mol. (ICAM)-1, cyclooxygenase-2, IL-6, IL-8, granulocyte macrophage-colony-stimulating factor (GM-CSF), regulated on activation normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), growth-regulated oncogene-α (GROα), neutrophil-activating protein-2 (NAP-2), and epithelial neutrophil activating peptide 78 (ENA-78) in primary human airways smooth muscle cells. Because this cell type is central to the pathogenesis of airway inflammatory diseases, these data predict a beneficial effect of IKK2 inhibition. These validated outputs were therefore used to evaluate the novel IKK inhibitors N-(6-chloro-9H-β-carbolin-8-yl) nicotinamide (PS-1145) and N-(6-chloro-7-methoxy-9H-β-carbolin-8-yl)-2-methyl-nicotinamide (ML120B) on IL-1β and TNFα-induced expression, and this was compared with the corticosteroid dexamethasone. As observed above, ICAM-1, IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROα, NAP-2, and ENA-78 expression was reduced by the IKK inhibitors. Furthermore, this inhibition was either as effective, or for ICAM-1, MCP-1, GROα, and NAP-2, more effective, than a maximally effective concentration of dexamethasone. We therefore suggest that IKK inhibitors may be of considerable benefit in inflammatory airways diseases, particularly in COPD or severe asthma, in which corticosteroids are ineffective.

IT 431898-65-6, PS-1145 783348-36-7, ML120B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(validation of anti-inflammatory properties of small-mol. IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-neg. IKK1 and IKK2 in human airways smooth muscle)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:524316 CAPLUS Full-text
DOCUMENT NUMBER: 145:116993
TITLE: Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ
AUTHOR(S): Nagashima, Kumiko; Sasseville, Vito G.; Wen, Danyi; Bielecki, Andrew; Yang, Hua; Simpson, Chris; Grant, Ethan; Hepperle, Michael; Harriman, Gerry; Jaffee, Bruce; Ocain, Tim; Xu, Yajun; Fraser, Christopher C.
CORPORATE SOURCE: Millennium Pharmaceuticals, Cambridge, MA, USA
SOURCE: Blood (2006), 107(11), 4266-4273
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The transcription factor NF-κB plays a central role in regulating inflammation and apoptosis, making it a compelling target for drug development. We identified a small mol. inhibitor (ML 120B) that specifically inhibits IKKβ, an Iκ-B kinase that regulates NF-κB. IKKβ and NF-κB are required in vivo for prevention of TNFα-mediated apoptosis. ML 120B sensitized mouse bone marrow

progenitors and granulocytes, but not mature B cells to TNFα killing in vitro, and induced apoptosis in vivo in the bone marrow and spleen within 6 h of a single oral dose. In vivo inhibition of IKKβ with ML 120B resulted in depletion of thymocytes and B cells in all stages of development in the bone marrow but did not deplete granulocytes. TNF receptor-deficient mouse thymocytes and B cells were resistant to ML 120B-induced depletion in vivo. Surprisingly, surviving bone marrow granulocytes expressed TNFR1 and TNFR2 after dosing in vivo with ML 120B. Our results show that inhibition of IKKβ with a small mol. in vivo leads to rapid TNF-dependent depletion of T and B cells. This observation has several implications for potential use of IKKβ inhibitors for the treatment of inflammatory disease and cancer.

IT 783348-36-7, ML 120B
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(ML 120B-induced IKKβ inhibition rapid TNFR1-dependent depletion of T- and B-cells in mice in relation to treatment of inflammatory disease and cancer)

RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:523948 CAPLUS Full-text
DOCUMENT NUMBER: 145:159386
TITLE: A selective small molecule IκB kinase β inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells
AUTHOR(S): Wen, Danyi; Nong, Yuhua; Morgan, Jennifer G.; Gangurde, Pranoti; Bielecki, Andrew; DaSilva, Jennifer; Keaveney, Marie; Cheng, Hong; Fraser, Chris; Schopf, Lisa; Hepperle, Michael; Harriman, Geraldine; Jaffee, Bruce D.; Ocain, Timothy D.; Xu, Yajun
CORPORATE SOURCE: Departments of Inflammation and Discovery Technologies, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2006), 317(3), 989-1001
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB IκB kinase (IKK) β is essential for inflammatory cytokine-induced activation of nuclear factor κB (NF-κB). NF-κB plays a pivotal role in the function of major cell types that contribute to the pathophysiol. process of rheumatoid arthritis (RA). Here, we report the mechanism and the effect of the IKKβ inhibitor N-(6-chloro-7-methoxy-9H-β-carbolin-8-yl)-2-methylnicotinamide (ML120B), a β-carboline derivative, on NF-κB signaling and gene activation in RA-relevant cell systems. ML120B is a potent, selective, reversible, and ATP-competitive inhibitor of IKKβ with an IC50 of 60 nM when evaluated in an IκBα kinase complex assay. ML120B does not inhibit other IKK isoforms or a panel of other kinases. ML120B concentration-dependently inhibits tumor necrosis factor α (TNFα)-stimulated NF-κB signaling via inhibition of IκBα phosphorylation, degradation, and NF-κB translocation into the nucleus. For the first time, we have demonstrated that in human fibroblast-like synoviocytes, TNFα- or interleukin (IL)-1β-induced monocyte chemoattractant protein-1 regulated on activation, normal T cell expressed and secreted and production is IKKβ-dependent. In addition, for the first time, we have demonstrated that lipopolysaccharide- or peptidoglycan-induced cytokine production in human cord blood-derived mast cells is IKKβ-dependent. In addition, in human chondrocytes, ML120B inhibited IL-1β-induced matrix metalloproteinase production with an IC50 of approx. 1 μM. ML120B also blocked IL-1β-induced prostaglandin E2 production In summary, ML120B blocked numerous NF-κB-regulated cell responses that are involved in inflammation and destructive processes in the RA joint. Our findings support the evaluation of IKKβ inhibitors as anti-inflammatory agents for the treatment of RA.

IT 783348-36-7, ML 120B
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective IKKβ inhibitor blocks NFκB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells)

RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:394205 CAPLUS Full-text
DOCUMENT NUMBER: 145:327824
TITLE: The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
AUTHOR(S): Cilloni, D.; Messa, F.; Arruga, F.; Defilippi, I.; Morotti, A.; Messa, E.; Carturan, S.; Giugliano, E.; Pautasso, M.; Bracco, E.; Rosso, V.; Sen, A.; Martinelli, G.; Baccarani, M.; Saglio, G.
CORPORATE SOURCE: Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
SOURCE: Leukemia (2006), 20(1), 61-67
CODEN: LEUKED; ISSN: 0887-6924
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Imatinib represents at present the most attractive therapy for BCR-ABL pos. leukemias, even though a percentage of CML patients develop resistance to this compound For these resistant patients a therapeutic approach based on a combination of drugs is more likely to be effective. In the last years, constitutive NF-κB/Rel activity has been demonstrated in several hematol. malignancies. As a result, NFkB/Rel-blocking approaches have been proposed as antineoplastic strategies. Furthermore, the identification of specific kinases within the NF-κB activation pathway offers a selective target to address tailored therapies. In the current study, we show that the IKK inhibitor PS1145 is able to inhibit the proliferation of CML cell lines and primary BM cells. Moreover, the addition of Imatinib increases the effects of PS1145 in resistant cell lines and BM cells from resistant patients, with a further increase of apoptosis and inhibition of proliferation and colony growth. Our data provide the rational for a new therapeutic approach, which combines Imatinib and the IKK inhibitor PS1145 in CML resistant patients.

IT 431898-65-6, PS1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(addition of Imatinib increased effects of IKK inhibitor PS1145 with further increase of apoptosis, inhibition of proliferation and colony growth in resistant CML cell lines and BM cells from resistant CML patient)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:66400 CAPLUS Full-text
DOCUMENT NUMBER: 144:121286
TITLE: NF-κB as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145
AUTHOR(S): Vodanovic-Jankovic, Sanja; Hari, Parameswaran; Jacobs, Paulette; Komorowski, Richard; Drobyski, William R.
CORPORATE SOURCE: Bone Marrow Transplant Program and the Departments of Medicine and Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
SOURCE: Blood (2006), 107(2), 827-834
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB NF-κB is a transcription factor that controls the expression of a number of genes important for mediating immune and inflammatory responses. In this study, we examined whether bortezomib and PS-1145, each of which inhibits NF-κB, could protect mice from lethal graft-vs.-host disease (GVHD), which is characterized by immune activation and proinflammatory cytokine production When administered within the first 2 days after transplantation, bortezomib and PS-1145 both protected mice from fatal GVHD, did not compromise donor engraftment, and effected marked reduction in the levels of serum cytokines that are normally increased during GVHD. Extending the course of bortezomib administration or delaying the initiation of this agent for as few as 3 days after bone marrow transplantation (BMT), however, significantly exacerbated GVHD-dependent mortality because of severe pathol. damage in the colon. In contrast, prolonged administration of PS-1145, which, unlike bortezomib, is a selective inhibitor of NF-κB, caused no early toxicity and resulted in more complete protection than that observed with an abbreviated PS-1145 treatment schedule. These results confirm a critical role for NF-κB in the pathophysiol. of GVHD and indicate that targeted inhibition of NF-κB may have a superior therapeutic index and may constitute a viable therapeutic approach to reduce GVHD severity.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NF-κB as a target for the prevention of graft-vs.-host disease: comparative efficacy of bortezomib and PS-1145)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:52335 CAPLUS Full-text
DOCUMENT NUMBER: 144:403881
TITLE: Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells
AUTHOR(S): Yemelyanov, A.; Gasparian, A.; Lindholm, P.; Dang, L.; Pierce, J. W.; Kisseljov, F.; Karseladze, A.; Budunova, I.
CORPORATE SOURCE: Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
SOURCE: Oncogene (2006), 25(3), 387-398
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A key antiapoptotic transcription factor, nuclear factor kappa-B (NF-κB), is known to be critically important for tumor cell growth, angiogenesis and development of metastatic lesions. We and others showed previously that NF-κB transcription factor was constitutively activated in androgen-independent prostate carcinoma (PC) cell lines due to the upregulated activity of inhibitor of NF-κB kinases (IKK). In this work, using luciferase assay, electrophoretic mobility shift assay and Northern blot anal. of expression of endogenous κB-responsive genes, we demonstrate that a novel highly specific small-mol. IKK inhibitor, PS1145, efficiently inhibited both basal and induced NF-κB activity in PC cells. We found that PS1145 induced caspase 3/7-dependent apoptosis in PC cells and significantly sensitized PC cells to apoptosis induced by tumor necrosis factor alpha. We also showed that PS1145 inhibited PC cell proliferation. Effects of PS1145 on proliferation and apoptosis correlated with inhibition of interleukin (IL)-6, cyclin D1, D2, inhibitor of apoptosis (IAP)-1 and IAP-2 gene expression and decreased IL-6 protein level. In addition, we found that incubation with PS1145 inhibited the invasion activity of highly invasive PC3-S cells in invasion chamber assay in a dose-dependent manner. Overall, this study provides the framework for development of a novel therapeutic approach targeting NF-κB transcription factor to treat advanced PC.

IT 431898-65-6, PS1145
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells)
RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1155525 CAPLUS Full-text
DOCUMENT NUMBER: 143:422250
TITLE: Preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents
INVENTOR(S): Hepperle, Michael E.; Liu, Julie Fields; Soucy, Francois; Raman, Prakash; Little, Jeremy D.; Fleming, Paul E.; Reynolds, Dominic; Harriman, Geraldine C. B.
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 143 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050239781	A1	20051027	US 2005-101998	20050408
AU 2005243188	A1	20051124	AU 2005-243188	20050408
CA 2561859	A1	20051124	CA 2005-2561859	20050408
WO 2005111037	A1	20051124	WO 2005-US13812	20050408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735311	A1	20061227	EP 2005-779267	20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1976931	A	20070606	CN 2005-80019014	20050408

BR 2005009660	A	20071009	BR 2005-9660		20050408
JP 2007532582	T	20071115	JP 2007-507578		20050408
SG 154458	A1	20090828	SG 2009-4592		20050408
MX 2006011545	A	20070326	MX 2006-11545		20061005
IN 2006DN05815	A	20070831	IN 2006-DN5815		20061006
NO 2006004894	A	20070103	NO 2006-4894		20061026
ZA 2006008956	A	20080625	ZA 2006-8956		20061027
KR 2007014166	A	20070131	KR 2006-723401		20061108
PRIORITY APPLN. INFO.:			US 2004-560892P	P	20040409
			WO 2005-US13812	W	20050408

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:422250
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted β-carbolines I [Q = CH2, CH-R9; G = NR4R5, 3-7 membered (un)substituted heterocyclyl; R1 = H, halo, alkyl, amino, alkylamino; R2, R3 = independently H, halo, C1-2 aliphatic, alkoxy, haloalkyl; R4, each R = independently H, C1-6 aliphatic; R5 = (un)substituted C1-6 aliphatic; R9 = C1-3 aliphatic; and their pharmaceutically acceptable salts] were prepared as inhibitors of IκB kinase 2 (IKK-2) for the treatment of inflammatory or immune system diseases such as rheumatoid arthritis, asthma, psoriasis, chronic obstructive pulmonary disease, or cancer (particularly lymphoma). E.g., coupling of (S)-4-((S)-2-tert-butoxycarbonylaminopropyl)-6,6-dimethylmorpholine-3-carboxylic acid with 6-chloro-4-methyl-9H-β-carbolin-8-ylamine, Boc-deprotection, and acylation of amine salt with 2-methylnicotinic acid. Selected β-carbolines I displayed IC50 < 100 nM for inhibition of IkB kinase in in vitro and cell-based assays. I were selective for inhibiting IKK-2 as opposed to IKK-1.

IT 783349-59-7P 783349-60-0P 783349-69-9P
783349-70-2P 783349-79-1P 783349-81-5P
783349-82-6P 783349-83-7P 783349-84-8P
783349-90-6P 783350-38-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783349-59-7 CAPLUS
CN 4-Morpholinecarboxylic acid, 3-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-60-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(3S)-3-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-4-morpholinyl]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-69-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-4-[(2,2,2-trifluoroacetyl)amino]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783349-70-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-4-[(2,2,2-trifluoroacetyl)amino]-9H-pyrido[3,4-b]indol-8-yl]- (CA INDEX NAME)



RN 783349-79-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-81-5 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 783349-80-4
CMF C21 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 783349-82-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-83-7 CAPLUS
CN Carbamic acid, [(1S)-2-[(5S)-5-[[(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-84-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783350-38-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-amino-3-methylbutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 794501-53-4P 868058-28-0P 868058-29-1P
868058-30-4P 868058-31-5P 868058-32-6P
868058-33-7P 868058-34-8P 868058-35-9P
868058-36-0P 868058-37-1P 868058-38-2P
868058-39-3P 868058-40-6P 868058-41-7P
868058-42-8P 868058-43-9P 868058-44-0P
868058-45-1P 868058-46-2P 868058-47-3P
868058-48-4P 868058-49-5P 868058-50-8P
868058-51-9P 868058-52-0P 868058-53-1P
868058-54-2P 868058-55-3P 868058-56-4P
868058-57-5P 868058-58-6P 868058-59-7P
868058-60-0P 868058-61-1P 868058-62-2P
868058-63-3P 868058-64-4P 868058-65-5P
868058-66-6P 868058-67-7P 868058-68-8P
868058-69-9P 868058-70-2P 868058-71-3P
868058-72-4P 868058-73-5P 868058-74-6P
868058-75-7P 868058-76-8P 868058-77-9P
868058-78-0P 868058-79-1P 868058-80-4P
868058-81-5P 868058-82-6P 868058-83-7P
868058-84-8P 868058-85-9P 868058-86-0P
868058-87-1P 868058-88-2P 868058-89-3P
868058-90-6P 868058-91-7P 868058-92-8P
868058-94-0P 868058-95-1P 868058-96-2P
868058-97-3P 868058-98-4P 868058-99-5P
868059-00-1P 868059-01-2P 868059-02-3P
868059-03-4P 868059-04-5P 868059-05-6P
868059-06-7P 868059-07-8P 868059-08-9P
868059-09-0P 868059-10-3P 868059-11-4P
868059-12-5P 868059-13-6P 868059-14-7P
868059-15-8P 868059-16-9P 868059-17-0P
868059-18-1P 868059-19-2P 868059-20-5P
868059-21-6P 868059-22-7P 868059-23-8P
868059-24-9P 868059-25-0P 868059-26-1P
868059-27-2P 868059-28-3P 868059-29-4P
868059-30-7P 868059-31-8P 868059-32-9P
868059-33-0P 868059-34-1P 868059-35-2P
868059-36-3P 868059-37-4P 868059-38-5P
868059-39-6P 868059-40-9P 868059-41-0P
868059-42-1P 868059-43-2P 868059-44-3P
868059-45-4P 868059-46-5P 868059-47-6P
868140-14-1P 868140-17-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of substituted -carboline IB kinase 2 (IKK-2)
inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)
RN 794501-53-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,2-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-28-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(3-pyridinylmethyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-29-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-N-(6-methyl-9H-pyrido[3,4-b]indol-8-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 868058-30-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-31-5 CAPLUS
CN D-Proline, 1-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-32-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-33-7 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-34-8 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-cyclohexyl-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-35-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-36-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-37-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-38-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1R)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-39-3 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-ethyl-N,2,2-trimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-40-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(1,1-dimethylethyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-41-7 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-methoxy-N,2,2-trimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-42-8 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-[(3-methyl-4-pyridinyl)methyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-43-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[(2R)-2-[(methylamino)carbonyl]-1-pyrrolidinyl]-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-44-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(4-oxocyclohexyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-45-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-4-methyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-46-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3-hydroxy-3-methyl-1-pyrrolidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-47-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,4-difluoro-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-48-4 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(6-methoxy-3-pyridinyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-49-5 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(3-methyl-5-isoxazolyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-50-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-51-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-oxo-1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-52-0 CAPLUS
CN 4-Piperidineacetic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-53-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-54-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-55-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-

dimethyl-1-pyrrolidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-56-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[4-(3-methyl-2-oxo-1-imidazolidinyl)-1-piperidinyl]-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-57-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-58-6 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-difluoro-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-59-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-60-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-ethyl-2,2-dimethyl-N-(phenylmethyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-61-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-methyl-3-oxo-1-piperazinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-62-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(3-oxo-1-piperazinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-63-3 CAPLUS
CN D-Proline, 1-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-64-4 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(4-methyl-1-piperazinyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-65-5 CAPLUS
CN 4-Morpholineacetamide, N-[cis-4-(aminocarbonyl)cyclohexyl]-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-66-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-67-7 CAPLUS
CN Carbamic acid, [1-[[(3R)-3-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-4-morpholinyl]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-68-8 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-70-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(tetrahydro-1,4-oxazepin-4(5H)-yl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-71-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-72-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-73-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[3-[[(2-hydroxyethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-74-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-75-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-[[(2-hydroxyethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-76-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-difluoro-1-pyrrolidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-77-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-78-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-1-piperidinyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-79-1 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-4-piperidinyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-80-4 CAPLUS
CN Glycine, N-[[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-81-5 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(6-methoxy-3-pyridinyl)-2,2-dimethyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-82-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-[4-(trifluoromethyl)-1-piperidinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-83-7 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-2-pyrazinyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-84-8 CAPLUS
CN 4-Morpholineacetamide, N-(1-acetyl-4-piperidinyl)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-85-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-86-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[4-(acetylamino)-1-piperidinyl]-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-87-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[4-(2-amino-2-oxoethyl)-1-piperidinyl]-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-88-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2S)-2-(1-hydroxy-1-methylethyl)-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-89-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperazinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-[4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-91-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[(3aR,4S,7R,7aR)-octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl]-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-92-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-ethynyl-4-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-94-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-95-1 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-[1-(methylsulfonyl)-4-piperidinyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-96-2 CAPLUS
CN 4-Piperidineacetic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-97-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[3-(aminocarbonyl)-1-piperidinyl]-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-98-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-99-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3R)-3-hydroxy-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-00-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-dimethyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-01-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2S,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-02-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[3-[(diethylamino)carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-03-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[4-[(methylsulfonyl)amino]-1-piperidinyl]-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-04-5 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-2-pyridinyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-05-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, rel- (CA

INDEX NAME)

Relative stereochemistry.



RN 868059-06-7 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[4-(aminocarbonyl)-1-piperidinyl]-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 868059-07-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-7-hydroxy-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 868059-08-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[(2R)-2-(aminocarbonyl)-1-pyrrolidinyl]-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-09-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-[(3,3-difluoro-1-pyrrolidinyl)carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-10-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-11-4 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2-furanylmethyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-12-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6R)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-13-6 CAPLUS
CN 4-Morpholineacetamide, N-[1-(aminocarbonyl)cyclohexyl]-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-14-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-oxo-2,8-diazaspiro[4.5]dec-8-yl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-15-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-(4-amino-1-piperidinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-16-9 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-4-morpholinyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-17-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-cyclohexyl-N-ethyl-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-18-1 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-19-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,4-dimethyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-20-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-21-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-ethyl-N-(2-hydroxyethyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-22-7 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2-furanylmethyl)-N,2,2-trimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-23-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-24-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-

[(ethylamino)carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 868059-25-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-26-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-27-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-[4-(1-pyrrolidinylsulfonyl)-1-piperazinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-28-3 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-ethyl-2,2-dimethyl-N-(4-pyridinylmethyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-29-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-3-(2,2,6,6-tetramethyl-4-piperidinyl)propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-30-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1,1-dioxido-4-thiomorpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-31-8 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-[(3-fluoro-4-pyridinyl)methyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-32-9 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-ethyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-33-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-4-phenyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-34-1 CAPLUS
CN 2-Aziridinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-35-2 CAPLUS
CN 4-Piperidineacetic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-hydroxy-α,α-dimethyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-36-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-hydroxy-4-(trifluoromethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-37-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(2-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-38-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(2,2,6,6-tetramethyl-4-morpholinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-39-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-[(dimethylamino)sulfonyl]-1-piperazinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-40-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-(4-benzoyl-1-piperazinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-41-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-1-piperidinyl]-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-42-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[3,3-dimethyl-4-[(methylsulfonyl)amino]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-43-2 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(3-methyl-5-isothiazolyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-44-3 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N,N-diethyl-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-45-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-46-5 CAPLUS

CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-1H-indol-5-yl-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-47-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(2-pyridinylmethyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868140-14-1 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(4-hydroxy-4-methylcyclohexyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 868140-17-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-[(dimethylamino)carbonyl]cyclohexyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783348-96-9P 783349-03-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)
RN 783348-96-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminobutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-03-1 CAPLUS
CN 4-Morpholineacetic acid, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783348-36-7P 783348-37-8P 783348-38-9P
783348-39-0P 783348-40-3P 783348-41-4P
783348-42-5P 783348-43-6P 783348-44-7P
783348-45-8P 783348-46-9P 783348-48-1P
783348-49-2P 783348-50-5P 783348-51-6P
783348-52-7P 783348-53-8P 783348-54-9P
783348-55-0P 783348-57-2P 783348-58-3P
783348-59-4P 783348-61-8P 783348-62-9P
783348-63-0P 783348-64-1P 783348-65-2P
783348-66-3P 783348-67-4P 783348-69-6P
783348-71-0P 783348-72-1P 783348-73-2P
783348-74-3P 783348-75-4P 783348-76-5P
783348-78-7P 783348-80-1P 783348-81-2P
783348-82-3P 783348-84-5P 783348-85-6P
783348-86-7P 783348-87-8P 783348-88-9P
783348-89-0P 783348-90-3P 783348-91-4P
783348-92-5P 783348-93-6P 783348-94-7P
783348-95-8P 783348-97-0P 783348-98-1P
783348-99-2P 783349-00-8P 783349-01-9P
783349-02-0P 783349-04-2P 783349-06-4P
783349-07-5P 783349-08-6P 783349-09-7P
783349-10-0P 783349-11-1P 783349-12-2P
783349-13-3P 783349-14-4P 783349-15-5P
783349-16-6P 783349-17-7P 783349-18-8P
783349-19-9P 783349-20-2P 783349-21-3P
783349-22-4P 783349-23-5P 783349-24-6P
783349-25-7P 783349-26-8P 783349-27-9P
783349-28-0P 783349-29-1P 783349-30-4P
783349-31-5P 783349-32-6P 783349-94-0P
783349-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-37-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-4-methyl- (CA INDEX NAME)



RN 783348-38-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-ethoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-39-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(dimethylamino)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-40-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[6-chloro-7-(4-methyl-1-piperazinyl)-9H-pyrido[3,4-b]indol-8-yl]- (CA INDEX NAME)



RN 783348-41-4 CAPLUS
CN 3-Furancarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-42-5 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1,2,2-trimethyl-5-oxo- (CA INDEX NAME)



RN 783348-43-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4,6,6-trimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-44-7 CAPLUS
CN 3-Furancarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-45-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(cyclopropylmethoxy)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-46-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-[2-(dimethylamino)ethoxy]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-48-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1-[2-(dimethylamino)ethyl]-5-oxo- (CA INDEX NAME)



RN 783348-49-2 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-1-[2-(dimethylamino)ethyl]-5-oxo- (CA INDEX NAME)



RN 783348-50-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-fluoro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-51-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(methylthio)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-52-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(ethylthio)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-53-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-[[2-(dimethylamino)ethyl]thio]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-54-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-methyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-55-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-57-2 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-58-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-59-4 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-61-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-62-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-63-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-amino-6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-64-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-amino-6-chloro-9H-pyrido[3,4-b]indol-8-yl)-
(CA INDEX NAME)



RN 783348-65-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-
(CA INDEX NAME)



RN 783348-66-3 CAPLUS
CN 2H-1,3-Thiazine-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-
yl)tetrahydro-, 1,1-dioxide (CA INDEX NAME)



RN 783348-67-4 CAPLUS
CN 3-Furancarboxamide, N-[6-chloro-7-[2-(dimethylamino)ethoxy]-9H-pyrido[3,4-b]indol-8-yl]tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-69-6 CAPLUS
CN 1,8-Dioxaspiro[4.5]decane-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-oxo- (CA INDEX NAME)



RN 783348-71-0 CAPLUS
CN 1-Oxaspiro[4.5]decane-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-oxo- (CA INDEX NAME)



RN 783348-72-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[6-chloro-7-(4-morpholinyl)-9H-pyrido[3,4-b]indol-8-yl]- (CA INDEX NAME)



RN 783348-73-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(4-morpholinyl)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-74-3 CAPLUS
CN 3-Furancarboxamide, N-[6-chloro-7-[2-(diethylamino)ethoxy]-9H-pyrido[3,4-b]indol-8-yl]tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-75-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-76-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2,2,2-trifluoroacetyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-78-7 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetylamino)propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-80-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(methylsulfonyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-81-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[[(4,6-dimethyl-5-pyrimidinyl)carbonyl]amino]propyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-82-3 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-84-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-morpholinylcarbonyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-85-6 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[[[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-86-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(5-methyl-3-isoxazolyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-87-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[(2-amino-2-methyl-1-oxopropyl)amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-88-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(methylamino)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-89-0 CAPLUS
CN Carbamic acid, [(1S)-2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-90-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[[(2,4-dimethyl-3-pyridinyl)carbonyl]amino]propyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-91-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-pyrazinylcarbonyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-92-5 CAPLUS
CN 3,4-Pyridinedicarboxamide, N4-[(1S)-2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-N3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-93-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(4-methyl-5-pyrimidinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-94-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(4-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 783348-95-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-97-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 783348-98-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-99-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[[(tetrahydro-3-furanyl)carbonyl]amino]butyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-00-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-01-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetylamino)propyl]-N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-02-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-04-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-06-4 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1-[2-(dimethylamino)ethyl]-5-oxo-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 783349-07-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-7-fluoro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 783349-08-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-[[2-(dimethylamino)ethyl]thio]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 783349-09-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-10-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-11-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-12-2 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-13-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-14-4 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-15-5 CAPLUS
CN 2H-1,3-Thiazine-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-, 1,1-dioxide, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 783349-16-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-17-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-18-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-19-9 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-

yl)amino]carbonyl]-N-(2-hydroxyethyl)-N,2,2-trimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-20-2 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-4-pyridinyl-, hydrochloride (1:1), (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-21-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-22-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 783349-23-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-24-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N,N,2,2-tetramethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-25-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-26-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-27-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-

b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-28-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,2-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 783349-29-1 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(trans-4-hydroxycyclohexyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-30-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-31-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-32-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(2-oxo-1-pyrrolidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-94-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-3-pyridinyl-, hydrochloride (1:1), (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-95-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-dimethyl-4-oxo-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L3 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1026485 CAPLUS Full-text
DOCUMENT NUMBER: 143:299106
TITLE: Methods using IκB kinase (IKK)) inhibitors for treating or preventing graft-vs.-host disease
INVENTOR(S): Blazar, Bruce R.; O'Shaughnessy, Matthew J.; Vogtenhuber, Christine; Serody, Jonathan S.; Baldwin, Albert S.
PATENT ASSIGNEE(S): University of North Carolina at Chapel Hill, USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 374,222, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050208036	A1	20050922	US 2005-32630	20050110
US 20040166095	A1	20040826	US 2003-374222	20030225
PRIORITY APPLN. INFO.:			US 2003-374222 B2	20030225

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods are provided for administering alloreactive T cells to transplant recipients such that the risk of graft-vs.-host disease is reduced. The methodol. of the invention includes the use of IκB kinase inhibitors to inhibit NF-κB activation.

IT 431898-65-6, PS 1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IκB kinase inhibitors for treating or preventing graft-vs.-host disease)
RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



L3 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:666436 CAPLUS Full-text
DOCUMENT NUMBER: 143:301630
TITLE: Real-time imaging of ligand-induced IKK activation in intact cells and in living mice
AUTHOR(S): Gross, Shimon; Piwnica-Worms, David
CORPORATE SOURCE: Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
SOURCE: Nature Methods (2005), 2(8), 607-614
CODEN: NMAEA3; ISSN: 1548-7091
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The transcription factor NF-κB is a key regulator of cellular activation, proliferation and apoptosis. Defects in the NF-κB pathway contribute to a broad array of malignant, neurodegenerative and chronic inflammatory diseases. IKK-dependent IκBα degradation by the 26S proteasome is a critical NF-κB regulatory control point, which is emerging as an important target for drug development. To directly monitor regulation of IKK activation in intact organisms, the authors engineered an IKBα-firefly Luciferase (IκBα-FLuc) fusion reporter. In cultured cells and living animals, the reporter provided a continuous, noninvasive readout of the kinetics of ligand-induced IKK activation and the pharmacodynamics of selective inhibitors of both IKK and the 26S proteasome. This IκBα-FLuc reporter now permits continuous readout of IKK activation in vivo, facilitates development and validation of target-specific therapeutics, and complements conventional NF-KB transcriptional reporters for more complete temporal and regional investigations of the NF-κB signaling pathway in health and disease.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(real-time imaging of ligand-induced IκB protein kinase activation in intact cells and in living mice with liver inflammation and tumors and effect of drugs)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 38 THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:455511 CAPLUS Full-text
DOCUMENT NUMBER: 143:150744
TITLE: Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor
AUTHOR(S): Holt, Randi Utne; Baykov, Vadim; Ro, Torstein Baade; Brabrand, Sigmund; Waage, Anders; Sundan, Anders; Borset, Magne
CORPORATE SOURCE: Dept. of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
SOURCE: Haematologica (2005), 90(4), 479-488
CODEN: HAEMAX; ISSN: 0390-6078
PUBLISHER: Ferrata Storti Foundation
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Multiple myeloma is characterized by an accumulation of malignant plasma cells in the bone marrow. Inside the bone marrow, adhesion of myeloma cells to extracellular matrix proteins such as fibronectin may promote cell survival and induce drug resistance. In this work we examined the effect of hepatocyte growth factor (HGF) on the adhesion of myeloma cells and the signaling pathways involved. Cell adhesion expts. were performed with the human myeloma cell line INA-6 and primary myeloma cells. The HGF signaling pathway was studied in INA-6 cells with the use of antibodies against VLA-4 integrin, and with inhibitors of various intracellular signaling mols. We found that HGF stimulated adhesion of myeloma cells to fibronectin. This event was dependent on the α4 and β1 integrin subunits (VLA-4), but HGF did not increase the expression of integrins on the cell surface. Our findings suggest that HGF promotes myeloma cells to adhere via activation of the phosphatidylinositol 3-kinase (PI3K) pathway independently of AKT, but possibly through the involvement of nuclear factor κ B (NF-κB). INA-6 cells adhered to fibronectin after stimulation by insulin-like growth factor or stromal cell-derived factor 1α, but this adhesion was less dependent on PI3K than HGF-mediated adhesion. This work points to HGF as a pro-adhesive factor in cell adherence to the bone marrow matrix protein fibronectin, an event known to promote cancer cell survival and drug resistance. Inhibiting HGF, its receptor c-Met or the VLA-4 integrin may be beneficial to the myeloma patient.

IT 431898-65-6, PS-1145
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human myeloma cells adhere to fibronectin in response to hepatocyte growth factor)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:404628 CAPLUS Full-text
DOCUMENT NUMBER: 144:88189
TITLE: Synthesis of C-14-labeled novel IKK inhibitor: 2-[14C]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide
AUTHOR(S): Li, Yuexian; Prakash, Shimoga R.
CORPORATE SOURCE: Department of Drug Metabolism and Pharmacokinetics, Radiochemistry Group, Millennium Pharmaceuticals, Cambridge, MA, 02139, USA
SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48(5), 323-330
CODEN: JLCRD4; ISSN: 0362-4803
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:88189
AB 2-[14C]-N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide (also referred to as [14C]-PS-1145) was synthesized from [14C]-paraformaldehyde in five steps in an overall radiochem. yield of 15%. The key intermediate 1-[14C]-6-chloro-1,2,3,4-tetrahydro-β- carboline was obtained by Pictet-Spengler cyclization of chlorotryptamine with [14C]-paraformaldehyde. Similar reactions were conducted with tryptamine to address the generality of the methodol.
IT 431898-65-6P, PS-1145 872416-18-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of carbon-14-labeled N-(chloropyrido[3,4-b]indolyl)pyridinecarboxamide via Pictet-Spengler cyclization of chlorotryptamine with labeled paraformaldehyde)
RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 872416-18-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl-1-14C)-(9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:103274 CAPLUS Full-text
DOCUMENT NUMBER: 142:385267
TITLE: Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling
AUTHOR(S): Lam, Lloyd T.; Davis, R. Eric; Pierce, Jackie; Hepperle, Michael; Xu, Yajun; Hottelet, Maria; Nong, Yuhua; Wen, Danyi; Adams, Julian; Dang, Lenny; Staudt, Louis M.
CORPORATE SOURCE: Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
SOURCE: Clinical Cancer Research (2005), 11(1), 28-40
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Constitutive activation of the NF-κR pathway is required for survival of the activated B cell-like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL). Here we show that a small mol. IκB kinase (IKK) inhibitor, PS-1145, and related compds. are toxic for ABC DLBCL cell lines but not for cell lines derived from the other prevalent form of DLBCL, germinal center B cell-like

DLBCL. Treatment of ABC lines with these inhibitors rapidly induced a series of gene expression changes that were attributable to cessation of constitutive IKK activity, similar to changes induced by acute expression of genetic inhibitors of NF-κB, confirming the effectiveness and specificity of this compound Before cell death, inhibition of IKK also induced features of apoptosis and an arrest in the G1 phase of the cell cycle. To test further the specificity of this toxicity, an inducible form of NF-κB was created by fusing the p65 NF-κB subunit with the ligand-binding domain of the estrogen receptor (p65-ERD). In the presence of tamoxifen, p65-ERD reversed the toxicity of IKK inhibition and restored expression of many NF-κB target genes. Another subgroup of DLBCL, primary mediastinal B-cell lymphoma (PMBL), also expresses NF-κB target genes, and treatment of a PMBL cell line with an IKK inhibitor was toxic and induced gene expression changes of a distinct group of NF-κB target genes. These studies validate the NF-κB pathway as a promising therapeutic target in ABC DLBCL, PMBL, and other lymphomas that depend on the activity of NF-κB for survival and proliferation.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. IκB kinase inhibitor PS-1145 inhibited lipopolysaccharide-stimulated IL-6, TNF-α production in human peripheral blood mononuclear cell and cytotoxic in ABC DLBCL cell line OCI-Ly3, OCI-Ly10 by NF-κB gene expression)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 87 THERE ARE 87 CAPLUS RECORDS THAT CITE THIS RECORD (90 CITINGS)
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:99310 CAPLUS Full-text
DOCUMENT NUMBER: 142:191297
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
INVENTOR(S): Stephenson, Diane T.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009354	A2	20050203	WO 2004-US22692	20040715
WO 2005009354	A3	20060126		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050075341	A1	20050407	US 2004-891913	20040715

PRIORITY APPLN. INFO.: US 2003-488211P P 20030717
OTHER SOURCE(S): MARPAT 142:191297

AB The present invention provides compns. and methods for the treatment of ischemic-mediated central nervous system disorders or injuries. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic-mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor.

IT 431898-65-6, PS-1145
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for treatment of ischemic-mediated central nervous system disorders or injury)

RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:902377 CAPLUS Full-text
DOCUMENT NUMBER: 141:379803
TITLE: Preparation of substituted β-carboline IκB

kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents

INVENTOR(S): Hepperle, Michael E.; Liu, Julie Fields; Soucy, Francois; Ye, Yingchun; Murray, Robert S.; Prakash, Raman; Little, Jeremy D.; Castro, Alfredo; Mazdiyasni, Hormoz; Fleming, Paul E.; Reynolds, Dominic

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092167	A1	20041028	WO 2004-US11080	20040409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004230952	A1	20041028	AU 2004-230952	20040409
CA 2521300	A1	20041028	CA 2004-2521300	20040409
US 20040235839	A1	20041125	US 2004-821545	20040409
EP 1611134	A1	20060104	EP 2004-759390	20040409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009263	A	20060328	BR 2004-9263	20040409
CN 1802375	A	20060712	CN 2004-80016017	20040409
JP 2006522824	T	20061005	JP 2006-509889	20040409
IN 2005DN04409	A	20070831	IN 2005-DN4409	20050929
NO 2005004598	A	20051027	NO 2005-4598	20051006
ZA 2005008198	A	20070131	ZA 2005-8198	20051011

PRIORITY APPLN. INFO.:

US 2003-461468P	P	20030409
WO 2004-US11080	W	20040409

OTHER SOURCE(S): MARPAT 141:379803

GI



I



II

AB Substituted β-carbolines I [A = (un)substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl, thiomorpholinyl; R1 = H, halo, alkyl, amino, cyano, alkylamino, dialkylamino, alkoxy, aminocarbonyl, trifluoroacetylamino, aminomethyl; R2 = H, halo, alkyl, F3C; R3 = H, halo, alkyl, haloalkyl, alkoxy, hydroxy, amino, cyano, alkylamino, dialkylamino] such as II are prepared as inhibitors of IκB kinase 2 (IKK-2) for the treatment of inflammatory or immune system diseases such as rheumatoid arthritis, asthma, psoriasis, chronic obstructive pulmonary disease, or cancer (particularly lymphoma). E.g., cyclcondensation of 6-fluorotryptamine hydrochloride and glyoxalic acid monohydrate, decarboxylation of the product in acid followed by neutralization, oxidation with air in refluxing xylenes, chlorination with N-chlorosuccinimide in HCl solution, nitration with sodium nitrate and trifluoroacetic acid, nucleophilic aromatic substitution of the fluoride moiety with sodium methoxide, reduction of the nitro group with palladium and hydrogen, and acylation of the amine with 2-methylnicotinic acid and EDCI in pyridine yields II. Compds. in which ring A is either a 2-substituted-3-pyridinyl moiety or a 4-substituted-5-pyrimidinyl moiety are better inhibitors of IKK-2 than the corresponding unsubstituted heterocycle-containing compds.; compds. in which A is a 4,6,6-trisubstituted-3-morpholinyl moiety are the most effective of those compds. in which ring A is a morpholinyl moiety (no data).

IT 783349-59-7P 783349-60-0P 783349-69-9P
783349-70-2P 783349-79-1P 783349-81-5P
783349-82-6P 783349-83-7P 783349-84-8P
783349-90-6P 783350-38-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783349-59-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 3-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-60-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[(3S)-3-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-4-morpholinyl]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-69-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-4-[(2,2,2-trifluoroacetyl)amino]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783349-70-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-4-[(2,2,2-trifluoroacetyl)amino]-9H-pyrido[3,4-b]indol-8-yl]- (CA INDEX NAME)



RN 783349-79-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-81-5 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 783349-80-4
CMF C21 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 783349-82-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-83-7 CAPLUS
CN Carbamic acid, [(1S)-2-[(5S)-5-[[(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-84-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783350-38-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-amino-3-methylbutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783348-96-9P 783349-03-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)
RN 783348-96-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminobutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-03-1 CAPLUS
CN 4-Morpholineacetic acid, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783348-36-7P 783348-37-8P 783348-38-9P
783348-39-0P 783348-40-3P 783348-41-4P
783348-42-5P 783348-43-6P 783348-44-7P
783348-45-8P 783348-46-9P 783348-48-1P
783348-49-2P 783348-50-5P 783348-51-6P
783348-52-7P 783348-53-8P 783348-54-9P
783348-55-0P 783348-57-2P 783348-58-3P
783348-59-4P 783348-61-8P 783348-62-9P
783348-63-0P 783348-64-1P 783348-65-2P
783348-66-3P 783348-67-4P 783348-69-6P
783348-71-0P 783348-72-1P 783348-73-2P
783348-74-3P 783348-75-4P 783348-76-5P
783348-78-7P 783348-80-1P 783348-81-2P
783348-82-3P 783348-84-5P 783348-85-6P
783348-86-7P 783348-87-8P 783348-88-9P
783348-89-0P 783348-90-3P 783348-91-4P
783348-92-5P 783348-93-6P 783348-94-7P
783348-95-8P 783348-97-0P 783348-98-1P
783348-99-2P 783349-00-8P 783349-01-9P
783349-02-0P 783349-04-2P 783349-06-4P
783349-07-5P 783349-08-6P 783349-09-7P
783349-10-0P 783349-11-1P 783349-12-2P
783349-13-3P 783349-14-4P 783349-15-5P
783349-16-6P 783349-17-7P 783349-18-8P
783349-19-9P 783349-20-2P 783349-21-3P
783349-22-4P 783349-23-5P 783349-24-6P
783349-25-7P 783349-26-8P 783349-27-9P
783349-28-0P 783349-29-1P 783349-30-4P

783349-31-5P 783349-32-6P 783349-94-0P
783349-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of substituted β-carboline IκB kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783348-36-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-37-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-4-methyl- (CA INDEX NAME)



RN 783348-38-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-ethoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-39-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(dimethylamino)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-40-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[6-chloro-7-(4-methyl-1-piperazinyl)-9H-pyrido[3,4-b]indol-8-yl]- (CA INDEX NAME)



RN 783348-41-4 CAPLUS
CN 3-Furancarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-42-5 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1,2,2-trimethyl-5-oxo- (CA INDEX NAME)



RN 783348-43-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4,6,6-trimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-44-7 CAPLUS
CN 3-Furancarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-45-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(cyclopropylmethoxy)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-46-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-[2-(dimethylamino)ethoxy]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-48-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1-[2-(dimethylamino)ethyl]-5-oxo- (CA INDEX NAME)



RN 783348-49-2 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-1-[2-(dimethylamino)ethyl]-5-oxo- (CA INDEX NAME)



RN 783348-50-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-fluoro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-51-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(methylthio)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-52-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(ethylthio)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-53-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-[[2-(dimethylamino)ethyl]thio]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-54-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-methyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-55-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-57-2 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-58-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-59-4 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-61-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-62-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-63-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-amino-6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl- (CA INDEX NAME)



RN 783348-64-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-amino-6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-65-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-66-3 CAPLUS
CN 2H-1,3-Thiazine-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-, 1,1-dioxide (CA INDEX NAME)



RN 783348-67-4 CAPLUS
CN 3-Furancarboxamide, N-[6-chloro-7-[2-(dimethylamino)ethoxy]-9H-pyrido[3,4-b]indol-8-yl]tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-69-6 CAPLUS
CN 1,8-Dioxaspiro[4.5]decane-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-oxo- (CA INDEX NAME)



RN 783348-71-0 CAPLUS
CN 1-Oxaspiro[4.5]decane-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-oxo- (CA INDEX NAME)



RN 783348-72-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[6-chloro-7-(4-morpholinyl)-9H-pyrido[3,4-b]indol-8-yl]- (CA INDEX NAME)



RN 783348-73-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-(4-morpholinyl)-9H-pyrido[3,4-b]indol-8-yl]-2-methyl- (CA INDEX NAME)



RN 783348-74-3 CAPLUS
CN 3-Furancarboxamide, N-[6-chloro-7-[2-(diethylamino)ethoxy]-9H-pyrido[3,4-b]indol-8-yl]tetrahydro-2,2-dimethyl-5-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-75-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 783348-76-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2,2,2-trifluoroacetyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-78-7 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetylamino)propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-80-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(methylsulfonyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-81-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[[(4,6-dimethyl-5-pyrimidinyl)carbonyl]amino]propyl]-6,6-dimethyl-, (3S)-

(CA INDEX NAME)

Absolute stereochemistry.



RN 783348-82-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 783348-84-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-morpholinylcarbonyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-85-6 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[[[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-86-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(5-methyl-3-isoxazolyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-87-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[(2-amino-2-methyl-1-oxopropyl)amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-88-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(methylamino)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-89-0 CAPLUS
CN Carbamic acid, [(1S)-2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-90-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[[(2,4-dimethyl-3-pyridinyl)carbonyl]amino]propyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-91-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-pyrazinylcarbonyl)amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-92-5 CAPLUS
CN 3,4-Pyridinedicarboxamide, N4-[(1S)-2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-N3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-93-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(4-methyl-5-pyrimidinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-94-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(4-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-95-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-, (3S)- (CA

INDEX NAME)

Absolute stereochemistry.



RN 783348-97-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-98-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-99-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[[(tetrahydro-3-furanyl)carbonyl]amino]butyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-00-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-01-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetylamino)propyl]-N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-02-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-04-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-06-4 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1-[2-

(dimethylamino)ethyl]-5-oxo-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 783349-07-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-fluoro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 783349-08-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-chloro-7-[[2-(dimethylamino)ethyl]thio]-9H-pyrido[3,4-b]indol-8-yl]-2-methyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 783349-09-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-10-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-11-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-12-2 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-13-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-14-4 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-15-5 CAPLUS
CN 2H-1,3-Thiazine-4-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-, 1,1-dioxide, hydrochloride (1:2) (CA INDEX NAME)



RN 783349-16-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-17-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-18-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-19-9 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2-hydroxyethyl)-N,2,2-trimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-20-2 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-4-pyridinyl-, hydrochloride (1:1), (5S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 783349-21-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-22-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-23-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-24-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N,N,2,2-tetramethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-25-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-26-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-27-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(5S)-5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-28-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,2-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 783349-29-1 CAPLUS

CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(trans-4-hydroxycyclohexyl)-2,2-dimethyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-30-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-31-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-32-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(2-oxo-1-pyrrolidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-94-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-3-pyridinyl-, hydrochloride (1:1), (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-95-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-dimethyl-4-oxo-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:485903 CAPLUS Full-text
DOCUMENT NUMBER: 139:207080
TITLE: Novel IKK inhibitors: β-carbolines
AUTHOR(S): Castro, Alfredo C.; Dang, Luan C.; Soucy, Francois; Grenier, Louis; Mazdiyasni, Hormoz; Hottelet, Maria; Parent, Lana; Pien, Christine; Palombella, Vito; Adams, Julian
CORPORATE SOURCE: Millennium Pharmaceuticals Inc., Cambridge, MA, 02139, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2419-2422
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:207080

AB Inhibitors of IκB kinase (IKK) have long been sought as specific regulators of NF-κB. A screening effort of the endogenous IKK complex allowed us to identify 5-bromo-6-methoxy-β-carboline as a nonspecific IKK inhibitor. Optimization of this β-carboline natural product derivative resulted in a novel class of selective IKK inhibitors with IC50s in the nanomolar range. In addition, we show that one of these β-carboline analogs inhibits the phosphorylation of IκBα and subsequent activation of NF-κB in whole cells, as well as blocking TNF-α release in LPS-challenged mice.

IT 431882-80-3 431887-65-9 431898-65-6 590398-98-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and structure-activity relationship of β-carbolines as novel IKK inhibitors)

RN 431882-80-3 CAPLUS
CN 4-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-65-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431898-65-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 590398-98-4 CAPLUS
CN 4-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 82 THERE ARE 82 CAPLUS RECORDS THAT CITE THIS RECORD (82 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:376638 CAPLUS Full-text
DOCUMENT NUMBER: 138:379205
TITLE: Use of inhibitors of IκB kinase for the treatment of cancer
INVENTOR(S): Adams, Julian
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039545	A2	20030515	WO 2002-US35645	20021106
WO 2003039545	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352498	A1	20030519	AU 2002-352498	20021106
EP 1443927	A2	20040811	EP 2002-789471	20021106
EP 1443927	B1	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005529842	T	20051006	JP 2003-541836	20021106
US 20050049265	A1	20050303	US 2004-495041	20041012
HK 1069311	A1	20071026	HK 2005-101152	20050212
PRIORITY APPLN. INFO.:			US 2001-344911P P	20011107
			WO 2002-US35645 W	20021106

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:379205

AB The invention discloses the use of inhibitors of IκB kinase to inhibit the growth of a cancer cell and to treat cancer, including multiple myeloma. Preparation and biol. testing of N-(6-chloro-9H-β-carbolin-8-yl)nicotinamide is described.

IT 431898-65-6P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IκB kinase inhibitors for treatment of cancer)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:405760 CAPLUS Full-text

DOCUMENT NUMBER: 137:6093

TITLE: Preparation of substituted beta-carbolines as potential therapeutics in diseases associated with increased IκB kinase activity

INVENTOR(S): Ritzeler, Olaf; Castro, Alfredo; Grenier, Louis; Soucy, Francois; Hancock, Wayne W.; Mazdiyasni, Hormoz; Palombella, Vito; Adams, Julian

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1209158	A1	20020529	EP 2000-125169	20001118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2402549	A1	20010920	CA 2001-2402549	20010228
WO 2001068648	A1	20010920	WO 2001-EP2237	20010228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001037418	A	20010924	AU 2001-37418		20010228
BR 2001009161	A	20021126	BR 2001-9161		20010228
EP 1268477	A1	20030102	EP 2001-909799		20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 2003000894	A2	20030728	HU 2003-894		20010228
HU 2003000894	A3	20080528			
JP 2003527394	T	20030916	JP 2001-567739		20010228
EE 200200523	A	20040415	EE 2002-523		20010228
NZ 521386	A	20040625	NZ 2001-521386		20010228
RU 2277095	C2	20060527	RU 2002-127682		20010228
AU 2001237418	B2	20070111	AU 2001-237418		20010228
CN 100509810	C	20090708	CN 2001-806470		20010228
IL 151695	A	20090922	IL 2001-151695		20010228
CZ 301077	B6	20091029	CZ 2002-3031		20010228
US 20020099068	A1	20020725	US 2001-812785		20010315
US 6627637	B2	20030930			
MX 2002007981	A	20040405	MX 2002-7981		20020816
NO 2002004338	A	20021105	NO 2002-4338		20020911
NO 324248	B1	20070917			
KR 826817	B1	20080502	KR 2002-712072		20020913
US 20040110759	A1	20040610	US 2003-627978		20030728
US 7026331	B2	20060411			
US 20060166978	A1	20060727	US 2006-390287		20060328
US 7348336	B2	20080325			

PRIORITY APPLN. INFO.:	EP 2000-105514	A 20000315
	EP 2000-125169	A 20001118
	WO 2001-EP2237	W 20010228
	US 2001-812785	A1 20010315
	US 2003-627978	A1 20030728

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:6093

GI



I

AB Carbolines I (B6, B7, B8, B9 = C, N, no more than 2 N's at the same time; R1-R4, R8 = H, halogen, OH, CN, sulfo, NO2, alkoxy, substituted amino, substituted amide, CO2H, substituted hydroxy, ketone, ester, aryl, O-aryl, substituted aryl, O-substituted aryl, alkyl, substituted alkyl, CF3, CF2CF3;

R5 = H, alkyl, alkyl radical, ketone, sulfo; R6, R7 = H, halogen, OH, Me, O-alkyl, O-substituted alkyl, substituted amino) were prepared as potential therapeutics for diseases associated with increased activity of IκB kinase. Thus, norharmane was treated with bromine to give 7-bromo-β-carboline (II). II had an IC50 value of 0.4 μM in a IκB kinase in an assay using IκB kinase complex prepared from HeLa S3 cell exts.

IT 431882-81-4P 431886-97-4P 431887-07-9P
431887-08-0P 431887-09-1P 431887-46-6P
431887-47-7P 431887-51-3P 431887-58-0P
431887-65-9P 431887-70-6P 431887-72-8P
431888-64-1P 431889-19-9P 431889-21-3P
431889-22-4P 431889-28-0P 431889-30-4P
431889-36-0P 431889-47-3P 431889-63-3P
431889-77-9P 431890-04-9P 431898-66-7P
431898-71-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted beta-carbolines as potential therapeutics in diseases associated with increased IκB kinase activity)

RN 431882-81-4 CAPLUS

CN 4-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 431882-80-3
CMF C17 H11 Cl N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 431886-97-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-07-9 CAPLUS
CN 2-Furancarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-08-0 CAPLUS
CN 2-Thiophenecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-09-1 CAPLUS
CN 3-Furancarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-5-(trifluoromethyl)- (CA INDEX NAME)



RN 431887-46-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-3-(1,1-dimethylethyl)-1-methyl- (CA INDEX NAME)



RN 431887-47-7 CAPLUS
CN 5-Isoxazolecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-51-3 CAPLUS
CN 3-Isoxazolecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-5-methyl- (CA INDEX NAME)



RN 431887-58-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-65-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-70-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431887-72-8 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-
(CA INDEX NAME)



RN 431888-64-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-5-oxo-,
(2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 431889-19-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-5-oxo-,
(2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 431889-21-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1,2-dihydro-2-oxo- (CA INDEX NAME)



RN 431889-22-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1-(1,1-dimethylethyl)-3-methyl- (CA INDEX NAME)



RN 431889-28-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1,3-dimethyl- (CA INDEX NAME)



RN 431889-30-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-3-(1,1-dimethylethyl)-1-(phenylmethyl)- (CA INDEX NAME)



RN 431889-36-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 431889-47-3 CAPLUS
CN 2-Furancarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)tetrahydro-5-oxo-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 431889-63-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-7-hydroxy-9H-pyrido[3,4-b]indol-8-yl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 431889-77-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431890-04-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



RN 431898-66-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 431898-65-6
CMF C17 H11 Cl N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 431898-71-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:371242 CAPLUS Full-text
DOCUMENT NUMBER: 137:304403
TITLE: NF-κB as a therapeutic target in multiple myeloma
AUTHOR(S): Hideshima, Teru; Chauhan, Dharminder; Richardson, Paul; Mitsiades, Constantine; Mitsiades, Nicholas; Hayashi, Toshiaki; Munshi, Nikhil; Dang, Lenny; Castro, Alfredo; Palombella, Vito; Adams, Julian; Anderson, Kenneth C.
CORPORATE SOURCE: Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA
SOURCE: Journal of Biological Chemistry (2002), 277(19), 16639-16647
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have shown that thalidomide (Thal) and its immunomodulatory derivs. (IMiDs), proteasome inhibitor PS-341, and As2O3 act directly on multiple myeloma (MM) cells and in the bone marrow (BM) milieu to overcome drug resistance. Although Thal/IMiDs, PS-341, and As2O3 inhibit nuclear factor (NF)-κB activation, they also have multiple and varied other actions. In this study, we therefore specifically address the role of NF-κB blockade in mediating anti-MM activity. To characterize the effect of specific NF-κB blockade on MM cell growth and survival in vitro, we used an IκB kinase (IKK) inhibitor (PS-1145). Our studies demonstrate that PS-1145 and PS-341 block TNFα-induced NF-κB activation in a dose- and time-dependent fashion in MM cells through inhibition of IκBα phosphorylation and degradation of IκBα, resp. Dexamethasone (Dex), which up-regulates IκBα protein, enhances blockade of NF-κB activation by PS-1145. Moreover, PS-1145 blocks the protective effect of IL-6 against Dex-induced apoptosis. TNFα-induced intracellular adhesion mol. (ICAM)-1 expression on both RPMI8226 and MM.1S cells is also inhibited by PS-1145. Moreover, PS-1145 inhibits both IL-6 secretion from BMSCs triggered by MM cell adhesion and proliferation of MM cells adherent to BMSCs. However, in contrast to PS-341, PS-1145 only partially (20-50%) inhibits MM cell proliferation, suggesting that NF-κB blockade cannot account

for all of the anti-MM activity of PS-341. Importantly, however, TNFα induces MM cell toxicity in the presence of PS-1145. These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu. Furthermore, they provide the framework for clin. evaluation of novel MM therapies based upon targeting NF-κB.

IT 431898-65-6, PS 1145
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NF-κB as a therapeutic target in multiple myeloma)

RN 431898-65-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 417 THERE ARE 417 CAPLUS RECORDS THAT CITE THIS RECORD (417 CITINGS)

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:81654 CAPLUS Full-text

DOCUMENT NUMBER: 114:81654

ORIGINAL REFERENCE NO.: 114:13937a,13940a

TITLE: Antiparasitic agents. Part XI. Synthesis and anthelmintic activity of 1-substituted 6-/8-[(2-carbomethoxyamino)benzimidazole]-5-carbonylamino-9H-pyrido[3,4-b] indoles

AUTHOR(S): Kumar, Pramod; Agarwal, Shiv K.; Bhakuni, D. S.

CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, 226 001, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1990), 29B(11), 1077-80
CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:81654

GI



I





II



AB 6/8-[(2-Carbomethoxyamino)benzimidazole]-5-carbonylamino-1-substituted-9 H-pyrido [3,4-b] indoles I (R = H, R2, R1 = H) and II (R3 = R2) were synthesized. Evaluation of anthelmintic activity against Ancylostoma ceylanicum, nippostrongylus brasiliensis, Hymenolepis nana and antiamoebic activity against Entamoeba histolytica shows that I (R = R4, R1 = H, R5 = H; R = R2, R1 = H) eliminate 81% infection of A. ceylanicum and I (R = R4, R1 = H, R5 = Ac) reduces 90% of worm in N. brasiliensis infection at 250 mg/kg dose. II (R3 = R4, R5 = H) is found to be active against E. histolytica at 31.25 μg/mL concentration

IT 132092-03-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and anthelmintic activity of)

RN 132092-03-6 CAPLUS

CN Carbamic acid, [5-[[(1-phenyl-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 11:32:49 ON 05 JAN 2010